

## Molecular Mechanisms of Pancreatic Bicarbonate Secretion

Min Goo Lee<sup>1</sup>, Yonjung Kim<sup>1</sup>, Ikhyun Jun<sup>1\*</sup>, Joydeep Aoun<sup>2</sup> and Shmuel Muallem<sup>2</sup>

<sup>1</sup>Department of Pharmacology, Brain Korea 21 PLUS Project for Medical Sciences, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, Korea.

<sup>2</sup>The Epithelial Signaling and Transport Section, Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, 20892

\* Present Address: The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul 03722, Korea  
e-mail: [mlee@yuhs.ac](mailto:mlee@yuhs.ac), [Shmuel.Muallem@nih.gov](mailto:Shmuel.Muallem@nih.gov)

Version 2.0, November 5<sup>th</sup>, 2020 [DOI: [10.3998/panc.2020.06](https://doi.org/10.3998/panc.2020.06)]

### I. Introduction

The human exocrine pancreas secretes 1-2 liters of pancreatic juice each day. When stimulated, the pancreas secretes alkaline pancreatic juice containing copious amounts of bicarbonate ( $\text{HCO}_3^-$ ) (27, 86).  $\text{HCO}_3^-$  plays essential roles in the digestive system.  $\text{HCO}_3^-$  determines the pH of bodily fluids as the major buffer system that guards against toxic pH fluctuations (133).  $\text{HCO}_3^-$  in pancreatic juice neutralizes gastric acid, and provides an optimal pH environment for digestive enzymes to function in the duodenum (86). In addition,  $\text{HCO}_3^-$  acts as a moderate chaotropic ion that facilitates the solubilization of macromolecules, such as digestive enzymes and mucins (47). The importance of pancreatic  $\text{HCO}_3^-$  secretion is highlighted in the abnormal  $\text{HCO}_3^-$  secretion in several forms of pancreatitis (118, 168) and in cystic fibrosis (CF), which causes poor mucin hydration and solubilization leading to obstruction of ductal structures of the pancreas, intestine, vas deferens and the lung (129, 130).

The exocrine pancreas is composed of three major cell types, acinar, duct and stellate cells. Acinar cells secrete a small volume of isotonic, plasma-like, NaCl-rich fluid and digestive enzymes. Duct cells modify the ionic composition of the fluid and secrete the bulk of the fluid and  $\text{HCO}_3^-$  of the pancreatic juice. Stellate cells may aid the

pancreas recovery from injury (82). As the main  $\text{HCO}_3^-$  secretor, the duct has key roles in the development of acute and chronic pancreatitis. At pH 7.4 and 5%  $\text{CO}_2$ , the  $\text{HCO}_3^-$  concentration in plasma is approximately 25 mM. In human, dog, cat, and guinea pig,  $\text{HCO}_3^-$  concentration in postprandial pancreatic juice is higher than 140 mM (27, 86). This remarkable transport performance has attracted much attention from pancreatologists and physiologists. Current understanding of the molecular mechanism of pancreatic  $\text{HCO}_3^-$  secretion was improved by the recent identification of ion transporters and channels, including the cystic fibrosis transmembrane conductance regulator (CFTR) (69), the electrogenic  $\text{Na}^+\text{-HCO}_3^-$  co-transporter NBCe1-B (also known as pNBC1) (1), and the solute-linked carrier 26 (SLC26) transporters (29, 116), together with regulatory proteins, such as with-no-lysine kinase 1 (WNK1) (119), STE20/SPS1-related proline/alanine-rich kinase (SPAK) (35) and the inositol-1,4,5-triphosphate ( $\text{IP}_3$ ) receptor binding protein released with  $\text{IP}_3$  (IRBIT) (163) and their role in pancreatic  $\text{HCO}_3^-$  secretion.

### II. Control of Pancreatic $\text{HCO}_3^-$ Secretion

Pancreatic  $\text{HCO}_3^-$  secretion increases in response

to ingestion of a meal and is regulated by multiple neurohumoral inputs. Fluid and enzyme secretion by acinar cells are controlled predominantly by an increase in cytoplasmic free  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_i$ ) (103, 123, 124). Fluid and  $\text{HCO}_3^-$  secretion by duct cells are regulated by the second messengers cAMP (86, 101) that synergizes with  $\text{Ca}^{2+}$  to generate the physiological response (4, 97, 122). Pancreatic ductal cells express receptors for a battery of hormones and neurotransmitters. The two major hormones controlling pancreatic fluid and  $\text{HCO}_3^-$  secretion are the  $\text{G}_s$ -coupled, cAMP generating hormone secretin and the  $\text{G}_q$ -coupled,  $\text{Ca}^{2+}$  mobilizing hormone cholecystokinin (CCK), which are released from gastrointestinal endocrine cells in the upper duodenum. Cholinergic vagal output via an enteropancreatic vagovagal reflex also has an important role in controlling ductal fluid and  $\text{HCO}_3^-$  secretion. In addition to these classic stimuli, several other humoral agents are released by the pancreas for fine tuning its secretion, including insulin, somatostatin, purines, and prostaglandins (90). Additional information on hormonal control of pancreatic secretion can be found in a previous review (86) and the "Regulation of Pancreatic Secretion" section in *Pancreapedia* (21).

## A. Humoral Control

### *Secretin*

The low pH (below 4.5) of gastric chyme stimulates the release of secretin from duodenal S cells into the blood (15, 22). Secretin stimulates ductal fluid and  $\text{HCO}_3^-$  secretion and synergizes with  $\text{Ca}^{2+}$  mobilizing agonists to potentiate enzyme secretion by acinar cells. Plasma secretin levels rise after a meal (22, 127) and correlate with  $\text{HCO}_3^-$  output (135). Secretin-stimulated fluid and  $\text{HCO}_3^-$  secretion is modulated directly or indirectly by both peptide hormones, such as CCK and somatostatin, and by vagal stimulation (43, 77, 167).

### *CCK*

CCK is a major stimulator of acinar cell enzyme

and fluid secretion which is mediated by the  $\text{Ca}^{2+}$ -dependent exocytosis of zymogen granules and activation of apical (luminal)  $\text{Cl}^-$  channels, respectively. The synaptotagmins are the  $\text{Ca}^{2+}$  sensor that convey the  $\text{Ca}^{2+}$  signal for pancreatic exocytosis (104) and  $\text{Ca}^{2+}$  activates the  $\text{Ca}^{2+}$ -activated Anoctamin 1 (TMEM16A) to initiate acinar cells fluid secretion (117). CCK also acts on pancreatic duct secretion; however, the effects of CCK on pancreatic duct differ among species. In humans, the effect of CCK alone on ductal fluid secretion is weak; however, CCK greatly potentiates the effects of secretin (167).

### *Purines*

Pancreatic duct cells express multiple purinergic type 2 receptor (P2Rs) types, including ionotropic P2X and metabotropic P2Y receptors at the apical and basolateral membranes (96). P2Rs are stimulated by purinergic ligands released from nerve terminals at the basolateral space, zymogen granules of acinar cells into the luminal space, or efflux by ductal ATP transporters to both the basolateral and luminal compartments (79). Stimulation of P2Rs increases  $[\text{Ca}^{2+}]_i$  in duct cells (112, 114). Several studies have examined effects of P2Rs on ion transporters in ductal cell lines, but there are almost no studies on ductal fluid and  $\text{HCO}_3^-$  secretion. Ishiguro et al. demonstrated that luminal ATP stimulated, while basolateral ATP inhibited fluid and  $\text{HCO}_3^-$  secretion in guinea-pig pancreatic duct (57). More recent studies examined the effect of various stimuli and ion channels of ATP release from ductal cell lines (79) that will be important to verify in native ducts.

## B. Neuronal Control


Pancreatic secretion is regulated by the enteric nervous system, which is composed of a gut-brain axis and an intrapancreatic system. The major neurotransmitter acting on pancreatic duct cells is acetylcholine released by vagal parasympathetic fibers. Duct cells express both M1 and M3 muscarinic receptors, which act through changes in  $[\text{Ca}^{2+}]_i$ . The M3 receptors may be more prominent

based on their higher expression level relative to the M1 receptors (36, 71). In humans, cholinergic stimulation enhances ductal secretion stimulated by secretin, likely by synergistic mechanism that is mediated by IRBIT (4, 122). Vasoactive intestinal peptide (VIP) and ATP are also localized in parasympathetic nerve terminals (78, 113). Vagal stimulation causes VIP release that is associated with fluid and  $\text{HCO}_3^-$  secretion (52, 64, 78).

### III. Key Transporters Involved in Pancreatic $\text{HCO}_3^-$ Secretion

Pancreatic  $\text{HCO}_3^-$  secretion is mediated by a coordinated function of transporters expressed in the apical and basolateral membranes of duct cells.

Pancreatic  $\text{HCO}_3^-$  secretion can be divided into 2 steps. The first step is uptake of  $\text{HCO}_3^-$  into duct cells from the blood through the basolateral membrane. The second step is efflux of  $\text{HCO}_3^-$  across the apical membrane of duct cells. Regulatory mechanisms in the cytosol that include ions like  $\text{Cl}^-$  and several kinases and phosphatases, act on the transporters to coordinate and integrate the secretory process. Recent advances in molecular, cellular, and physiological techniques have enhanced our understanding of the molecular identity, localization, function, and regulatory mechanisms of ductal ion transporters (4, 87, 97). The major ion transporters expressed in the apical and basolateral membranes of the pancreatic duct cells are summarized in **Table 1** and **Figure 1**.



**Figure 1.** A schematic diagram depicting the transporters and channels in the apical (luminal) and basolateral membranes of pancreatic duct cells. The main driving force for  $\text{HCO}_3^-$  secretion is achieved by the  $\text{Na}^+$  gradient generated by the  $\text{Na}^+/\text{K}^+$  ATPase pump and  $\text{K}^+$  channels at the basolateral membrane, which generate the intracellular negative membrane potential.  $\text{HCO}_3^-$  is loaded mainly through the electrogenic ( $1\text{Na}^+-2\text{HCO}_3^-$ ) NBCe1-B, and partly by NHE1 located in the basolateral membrane. Basolateral AE2 may act to supply  $\text{Cl}_{in}$  to maintain the secretion. Apical  $\text{HCO}_3^-$  secretion is performed by the interacting and functionally interrelated CFTR and Slc26a6. Transcellular  $\text{HCO}_3^-$  movement generates a lumen-negative electrical potential that results in paracellular  $\text{Na}^+$  secretion through the paracellular pathway. Water follows  $\text{Na}^+$  and  $\text{HCO}_3^-$  osmotically via paracellular and transcellular (aquaporins) pathways. In the resting state, luminal NHE3 and NBCn1-A function as salvage luminal  $\text{HCO}_3^-$ . Modified from (87).

**Table 1: Transporters of pancreatic duct**

<b>Transporters in the luminal membrane of pancreatic duct</b>		
<b>Transporters</b>	<b>Gene</b>	<b>Function</b>
cAMP-activated Cl <sup>-</sup> channel	CFTR (ABCC7)	Fluid and HCO <sub>3</sub> <sup>-</sup> secretion
Ca <sup>2+</sup> -activated Cl <sup>-</sup> channel	TMEM16/ANO family	Cl <sup>-</sup> and HCO <sub>3</sub> <sup>-</sup> (?) secretion, lipids flipping
Anion exchangers	SLC26A3 (DRA/CLD)	HCO <sub>3</sub> <sup>-</sup> secretion, electrogenic Cl <sup>-</sup> /HCO <sub>3</sub> <sup>-</sup> exchanger (Cl <sup>-</sup> :HCO <sub>3</sub> <sup>-</sup> stoichiometry of 2:1 or higher)
	PAT1 (SLC26A6)	HCO <sub>3</sub> <sup>-</sup> secretion, electrogenic Cl <sup>-</sup> /HCO <sub>3</sub> <sup>-</sup> exchanger (Cl <sup>-</sup> :HCO <sub>3</sub> <sup>-</sup> stoichiometry of 1:2)
Na <sup>+</sup> /H <sup>+</sup> exchangers	NHE3 (SLC9A3)	HCO <sub>3</sub> <sup>-</sup> reabsorption (HCO <sub>3</sub> <sup>-</sup> salvage mechanism)
	NHE2 (SLC9A2)	HCO <sub>3</sub> <sup>-</sup> reabsorption (?)
Na <sup>+</sup> -HCO <sub>3</sub> <sup>-</sup> cotransporter	NBCn1-A (NBC3, SLC4A7)	HCO <sub>3</sub> <sup>-</sup> reabsorption (HCO <sub>3</sub> <sup>-</sup> salvage mechanism)
K <sup>+</sup> channels	Maxi- K <sup>+</sup> channels (KCNMA1?)	Maintain membrane potential during stimulated secretion Modulate luminal HCO <sub>3</sub> <sup>-</sup> secretion
Water channel	Aquaporin 5 (AQP5)	H <sub>2</sub> O flow
<b>Transporters in the basolateral membrane of pancreatic duct</b>		
<b>Transporters</b>	<b>Gene</b>	<b>Function</b>
Na <sup>+</sup> /H <sup>+</sup> exchangers	NHE1 (SLC9A1)	Na <sup>+</sup> -coupled H <sup>+</sup> extrusion, pH <sub>in</sub> homeostasis Contribute to basolateral HCO <sub>3</sub> <sup>-</sup> influx
	NHE4 (SLC9A4)	Role uncertain
Na <sup>+</sup> -HCO <sub>3</sub> <sup>-</sup> cotransporters	NBCe1-B (pNBC1, SLC4A4)	Basolateral HCO <sub>3</sub> <sup>-</sup> entry
Anion exchangers	AE2 (SLC4A2)	pH <sub>in</sub> homeostasis, Cl <sub>in</sub> supplier (?)
Cation-chloride cotransporters	Na <sup>+</sup> -K <sup>+</sup> -2Cl <sup>-</sup> cotransporter (NKCC1, SLC12A2)	Basolateral Cl <sup>-</sup> uptake (in mouse and rat ducts, but not in guinea pig and human)
	K <sup>+</sup> -Cl <sup>-</sup> cotransporter (KCC1, SLC12A4)	Basolateral K <sup>+</sup> and Cl <sup>-</sup> efflux Cell volume regulation
K <sup>+</sup> channels	Maxi- K <sup>+</sup> channels (KCNMA1)	Maintain membrane potential during stimulated secretion
	Small or intermediate conductance K <sup>+</sup> channels (KCNN4)	Maintain resting membrane potential
Na <sup>+</sup> , K <sup>+</sup> -ATPase	Na <sup>+</sup> , K <sup>+</sup> -ATPase (ATP1B1-3)	Maintain inward Na <sup>+</sup> gradient and outward K <sup>+</sup> gradient that determines the membrane potential
Water channels	Aquaporin 1 (AQP1)	Water transport
	Aquaporin 5 (AQP5)	Water transport
Carbonic Anhydrases	CAXII	HCO <sub>3</sub> <sup>-</sup> supply to AE2 and NBCe1-B

## A. Na<sup>+</sup>/K<sup>+</sup> ATPase, and K<sup>+</sup> Channels

The main driving force for fluid secretion is achieved by the Na<sup>+</sup>/K<sup>+</sup> ATPase pump and K<sup>+</sup> channels which generate the transmembrane Na<sup>+</sup> and K<sup>+</sup> gradients and the negative intracellular membrane potential (87, 118). The Na<sup>+</sup>/K<sup>+</sup> ATPase pump is expressed in the basolateral membrane of the ducts (99, 134, 145, 150), and generates the Na<sup>+</sup> and K<sup>+</sup> gradients by extruding 3 Na<sup>+</sup> ions in exchange for uptake of 2 extracellular K<sup>+</sup> ions using the energy of ATP hydrolysis. K<sup>+</sup> channels in both the basolateral and apical membranes use the K<sup>+</sup> gradient generated by the pump to generate a negative membrane potential. The Na<sup>+</sup> gradient is used to drive several Na<sup>+</sup>-coupled solutes, including HCO<sub>3</sub><sup>-</sup> absorption by the basolateral Na<sup>+</sup>-HCO<sub>3</sub><sup>-</sup> cotransporter NBCe1-B and basolateral and luminal Na<sup>+</sup>/H<sup>+</sup> exchangers (NHEs). The negative membrane potential aids in controlling HCO<sub>3</sub><sup>-</sup> uptake by NBCe1-B and in HCO<sub>3</sub><sup>-</sup> efflux through luminal electrogenic transporters. MaxiK channels (KCNMA1) have been identified on the basolateral membrane of rat pancreatic duct cells, and are likely candidates for maintaining the membrane potential during agonist-stimulated HCO<sub>3</sub><sup>-</sup> secretion (38). A Ba<sup>2+</sup>-sensitive channel of 82 pS conductance (KCNN4) appears to be a basolateral K<sup>+</sup> channel, which is responsible for the resting K<sup>+</sup> permeability (115). Apical membrane K<sup>+</sup> channels were identified in acinar cells (5) and in pancreatic duct cells, with the later having a role in ductal HCO<sub>3</sub><sup>-</sup> secretion (155).

## B. Na<sup>+</sup>-HCO<sub>3</sub><sup>-</sup> Co-transporters (NBCs)

The main ductal basolateral membrane HCO<sub>3</sub><sup>-</sup> accumulation transporter is NBCe1-B (87). NBCe1-B was cloned from pancreas and was named pNBC1 (1). It was later re-named NBCe1-B as part of classification of the NBC family (14). NBCe1-B is an electrogenic transporter with a 1 Na<sup>+</sup>: 2 HCO<sub>3</sub><sup>-</sup> stoichiometry in pancreatic duct cells (42). NBCe1-B can be regulated by cAMP-dependent protein kinase A (PKA) phosphorylation at Ser1026 and Thr49 (41). In principle, Na<sup>+</sup>/H<sup>+</sup>

exchangers in the basolateral membrane (e.g. NHE1) can also mediate HCO<sub>3</sub><sup>-</sup> influx in duct cells. However, the electrogenic NBCe1-B utilizes the Na<sup>+</sup> gradient more efficiently than the electroneutral NHE1 (1 Na<sup>+</sup>: 1 HCO<sub>3</sub><sup>-</sup>). Indeed, NBCe1-B contributes up to ~75% of the HCO<sub>3</sub><sup>-</sup> influx during secretin-induced ductal fluid and HCO<sub>3</sub><sup>-</sup> secretion in guinea pig (60, 62). The activity of NBCe1-B is controlled by multiple inputs, including IRBIT and the WNK/Ste20-related proline/alanine-rich kinase (SPAK) pathway (143, 164) and most notably intracellular Cl<sup>-</sup> (138). A more recent analysis revealed an intricate regulation of NBCe1-B by the WNK and CaMKII (Ca<sup>2+</sup> and calmodulin activated kinase II) kinases and the SPAK and calcineurin phosphatases the dephosphorylate the serine residues phosphorylated by the respective kinases (153). The kinases/phosphatases pairs determine regulation of NBCe1-B by Cl<sub>in</sub><sup>-</sup> (153), which emerges as a new general form of signaling ion (97). In addition to NBCe1-B, the duct expresses electroneutral NBCn1-A (NBC3) on the apical (luminal) membrane (120, 128). This transporter may mediate HCO<sub>3</sub><sup>-</sup> salvage in the resting state to maintain acidified pancreatic juice (37, 100).

## C. CFTR

The discovery of acidic pancreatic juice in patients with cystic fibrosis (CF) was a milestone in understanding the mechanism of pancreatic HCO<sub>3</sub><sup>-</sup> secretion (65, 81). The CF transmembrane conductance regulator (CFTR) was discovered as the protein mutated in patients with CF (69, 131, 132). Although CFTR is a member of the ATP-binding cassette (ABC) transporter superfamily that usually act as membrane pumps that transport their substrates against the electrochemical gradient (24), CFTR functions as an anion (Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup>) channel, through which ions diffuse down the electrochemical gradient. CFTR is located at the apical membrane of pancreatic ducts (20, 148, 170) (and all secretory epithelia), and is activated by the cAMP/PKA pathway. At [Cl<sup>-</sup>]<sub>i</sub> higher than 10 mM, CFTR functions as a Cl<sup>-</sup> channel that has

limited permeability to  $\text{HCO}_3^-$  (92, 126, 137). However, when  $[\text{Cl}^-]_i$  drops to below 10 mM, CFTR anionic selectivity changes to increase  $\text{HCO}_3^-$  permeability and mediate luminal  $\text{HCO}_3^-$  exit (67, 119). Indeed, as has been shown in patients with CF (20, 56, 148), CFTR is critically involved in epithelial  $\text{HCO}_3^-$  secretion. This leads to revision of the original model of ductal  $\text{HCO}_3^-$  secretion, in which  $\text{Cl}^-/\text{HCO}_3^-$  exchangers mediate apical  $\text{HCO}_3^-$  efflux and CFTR facilitates the apical  $\text{Cl}^-/\text{HCO}_3^-$  exchangers by recycling the  $\text{Cl}^-$  (12). This continues to be the case at high  $\text{Cl}^-_{in}$ . However, at low  $[\text{Cl}^-]_i$ ,  $\text{HCO}_3^-$  efflux via CFTR driven by the membrane potential has essential role in  $\text{HCO}_3^-$  efflux and  $\text{HCO}_3^-$ -driven fluid secretion in the pancreatic duct (61, 147). The dynamic change in CFTR  $\text{Cl}^-/\text{HCO}_3^-$  permeability is mediated by the protein kinase WNK1 (70, 119). WNK1 (125) and other members of the WNK kinases are regulated by  $\text{Cl}^-_{in}$ , with high  $\text{Cl}^-_{in}$  in the low (WNK4) and high (WNK1) range inhibiting the WNKs. Reduction in  $\text{Cl}^-_{in}$  activates the WNKs that act directly or through SPAK on CFTR and other  $\text{HCO}_3^-$ ,  $\text{Na}^+$ ,  $\text{Cl}^-$  and  $\text{K}^+$  transporters (97). To regulate their activity and selectivity. It is of interest that the WNKs show differential sensitivity to  $\text{Cl}^-_{in}$  and effect on the transporters (151, 163). Thus, a modest reduction in  $\text{Cl}^-_{in}$  is sufficient to activate WNK1 and increase  $\text{HCO}_3^-$  transport by CFTR (119). Further reduction in  $\text{Cl}^-_{in}$  will activate WNK4 that inhibits CFTR activity (163), perhaps to prevent excess  $\text{HCO}_3^-$  secretion, that is energetically very expensive involving transport by multiple electrogenic transporters. The significance of CFTR-dependent  $\text{HCO}_3^-$  secretion in CFTR-expressing epithelia, including the pancreas, has been established in a study correlating CFTR-dependent  $\text{HCO}_3^-$  transport and severity of the CF disease (23). The importance of the shift in the WNK1-mediated shift in CFTR  $\text{HCO}_3^-$  selectivity has been clearly demonstrated in a study that examined pancreatitis-associated CFTR mutations with altered WNK1-mediated increase in  $\text{HCO}_3^-$  permeability and found clear correlation between reduced  $\text{HCO}_3^-$  permeability and chronic pancreatitis in humans (83).

CFTR has a more global role in ductal fluid and  $\text{HCO}_3^-$  secretion. In addition to functioning as a  $\text{Cl}^-$  and  $\text{HCO}_3^-$  channel, CFTR functions as a scaffold forming macromolecular complexes with other transporters and regulatory proteins at the apical membrane (87). CFTR has a PSD95/Disc-large/ZO-1 (PDZ) ligand at the C-terminus and binds to PDZ domains of adapter proteins, such as  $\text{Na}^+/\text{H}^+$  exchanger regulatory factors (NHERFs). It also has SH3 and multiple ankyrin repeat domains 2 (Shank2) (84, 144), through which CFTR interacts and regulates the activity of *slc26a6*, *slc26a3* (75), NHE3 (3) and NBCn1-A (120). Other interactions of CFTR are with soluble NSF attachment protein receptor (SNARE) proteins, A-kinase anchor proteins (AKAPs), kinases and phosphatases (44) that may serve to regulate CFTR activity and the activity of the transporters interacting with CFTR. The interaction with the SLC26 transporters is of particular significance since the two transporters are mutually activated when interacting (75, 76). The mutual regulation is mediated by interaction of the CFTR R domain with the SLC26 transporters STAS domain (76).

#### D. $\text{Cl}^-/\text{HCO}_3^-$ Exchangers

$\text{Cl}^-/\text{HCO}_3^-$  exchangers mediate the bulk of  $\text{HCO}_3^-$  exit across the apical membranes of the pancreatic duct cells until the last portion of  $\text{HCO}_3^-$  exit that is mediated by CFTR once it gains  $\text{HCO}_3^-$  permeability. In humans, members of the solute-linked carrier 4 (SLC4) and the SLC26 families function as  $\text{Cl}^-/\text{HCO}_3^-$  exchangers. Among the SLC4 transporters, duct cells express AE2 (SLC4A2) at the basolateral membrane that regulates  $\text{pH}_i$  and protects against alkaline load (118). However, our studies revealed an essential role for AE2 in ductal fluid and  $\text{HCO}_3^-$  secretion (53). Intuitively, basolateral  $\text{HCO}_3^-$  efflux mechanism should inhibit rather than stimulate ductal  $\text{HCO}_3^-$  secretion. It is not clear why AE2 is essential for ductal fluid secretion. Maintaining stable  $\text{pH}_i$  that neutralize acid load by the  $\text{Na}^+/\text{H}^+$  exchangers and high  $\text{pH}$  next to the plasma membrane is one potential critical function of AE2. Another possibility

is that AE2 may provide the duct with  $\text{Cl}^-$  that is needed to keep the luminal *slc26a6* functioning in a face of limited  $\text{Cl}^-$  provided by acinar secretion (53).

Among the SLC26 family transporters, SLC26A3, and SLC26A6 are located on the apical membrane of the pancreatic duct cells and mediate  $\text{Cl}^-/\text{HCO}_3^-$  exchange. Interestingly, SLC26A3 has a  $2\text{Cl}^-/1\text{HCO}_3^-$  stoichiometry (76, 139), while SLC26A6 functions as a  $2\text{HCO}_3^-/1\text{Cl}^-$  exchanger (72, 139). A persistent osmotic gradient is needed to support the copious fluid secretion by the pancreatic duct. This is satisfied by the coupled action of NBCe1-B and SLC26A6 that results in a continuous net  $\text{HCO}_3^-$  (osmolyte) transcellular transport and thus transcellular  $\text{H}_2\text{O}$  flow (140, 149, 159). In addition, as indicated above, SLC26 transporters interact with CFTR through the sulfate transporter and anti-sigma factor antagonist (STAS) domain, and regulate pancreatic secretion by activating CFTR (76). This form of regulation is critical for pancreatic and other exocrine glands  $\text{HCO}_3^-$  secretion, including the pancreas, salivary glands, the kidney and the lung (91).

### **E. Other Transporters, Channels, and Carbonic Anhydrases**

#### *Na<sup>+</sup>/H<sup>+</sup> exchangers (NHEs)*

The SLC9A NHE family contains electroneutral  $1\text{Na}^+/1\text{H}^+$  exchangers. The ubiquitous NHE1 (SLC9A1) is essential for intracellular pH homeostasis and supplies  $\text{Na}^+$  to the  $\text{Na}^+/\text{K}^+$  ATPase pump on the basolateral membrane of the pancreatic duct (171). Diffusion of  $\text{CO}_2$  from the blood into the duct and  $\text{CO}_2$  generated by metabolism is hydrated by the action of carbonic anhydrases to generate  $\text{HCO}_3^-$  and  $\text{H}^+$ . Consequently,  $\text{H}^+$  efflux by NHE1 may contribute to basolateral  $\text{HCO}_3^-$  uptake. However, NHE1 does not have a major role in basolateral  $\text{HCO}_3^-$  influx as revealed by minimal inhibition of fluid and  $\text{HCO}_3^-$  secretion by inhibition of NHE1 in pancreatic duct of most species (154, 162). The NHE3 isoform is expressed in the apical membrane of pancreatic

duct and is thought to mediate  $\text{HCO}_3^-$  salvage at the resting state (85). At the resting state, the pancreatic juice is acidic, indicating an active  $\text{H}^+$  secretion (37, 100) that may be mediated by the combined action of NHE3 and NBCn1-A. Similar to NBCn1-A (120), NHE3 interacts with CFTR via PDZ domain containing proteins (3), and is regulated by IRBIT (48, 49). However, the physiological significance of these transporters await evaluation in mouse models with targeted pancreatic deletion of ductal NHEs and NBCn1-A.

#### *Ca<sup>2+</sup>-activated Cl<sup>-</sup> channels (CaCCs)*

Several members of the anoctamin (TMEM16/ANO) family function as CaCC (18, 136, 166). TMEM16A/ANO1, TMEM16B/ANO2, TMEM16F/ANO6, TMEM16H/ANO8, and TMEM16K/ANO10 are expressed in pancreas (87). However, ANO1 is expressed in acinar but not duct cells (136), ANO6 functions as a flipase and as a  $\text{Cl}^-$  channel (150) and ANO8 is a tether at the ER/PM junctions that controls assembly of  $\text{Ca}^{2+}$  signaling complexes (63). The function of ANO2 and ANO10 in the pancreas is not clear at this time. Nevertheless, ample evidence shows that the pancreatic duct (and ducts of other secretory glands) has CaCC activity in the apical membrane (39, 40, 157, 169). The molecular identity of this channel is not known at present, nor its function in  $\text{HCO}_3^-$  secretion. ANO6 appears to function as a  $\text{Ca}^{2+}$ -activated  $\text{Cl}^-$  channel in the intestine that participates in fluid and electrolyte secretion (11), and may have a similar function on the pancreatic duct. Several other CaCCs are known and are candidates for the ductal CaCC. In pancreatic acinar cells and other serous cells, ANO1 may have a role in  $\text{HCO}_3^-$  transport. At physiological  $[\text{Ca}^{2+}]_i$  concentrations ANO1 functions as a  $\text{Cl}^-$  channel. However, at high  $[\text{Ca}^{2+}]_i$  and perhaps at high  $[\text{Ca}^{2+}]_i$  microdomains, ANO1  $\text{HCO}_3^-$  permeability is increased by  $\text{Ca}^{2+}$ /calmodulin (66, 68), raising the possibility that ANO1 can provide an alternative  $\text{Cl}^-$  and  $\text{HCO}_3^-$  conduction in acinar cells (142).

## *Aquaporins*

Although the paracellular pathway is permeable to H<sub>2</sub>O, H<sub>2</sub>O flows mostly transcellularly via the water channels aquaporins (AQP) family. This is best illustrated in salivary glands, where knockout of AQP5 markedly reduces salivation (98). Among the 13 AQPs, AQP1 and AQP5 are the major aquaporins in pancreatic duct (17, 73, 74). AQP1 is expressed in the luminal membrane of human acinar and duct cells and is significantly reduced in chronic pancreatitis (156). Moreover, deletion of AQP1 in mice prominently inhibits ductal and pancreatic fluid and HCO<sub>3</sub><sup>-</sup> secretion, due to both reduction in fluid transport and in CFTR expression and activity and thus HCO<sub>3</sub><sup>-</sup> secretion (156). The role of AQP5 in the duct and pancreatic secretion has not been established yet.

## *Carbonic Anhydrases*

A poorly studied topic that deserves more attention is the role of the ductal carbonic anhydrases (CAs) in fluid and electrolyte secretion, in particular with the emerging secretory epithelial diseases due to mutations in CAs. Mutations that affect the action of CA4 cause retinitis pigmentosa (7) and a mutation in CA12 causes salt wasting (32, 106). All transporters involved in fluid and HCO<sub>3</sub><sup>-</sup> secretion are affected by HCO<sub>3</sub><sup>-</sup> concentration at the cellular compartments and microdomains that determine HCO<sub>3</sub><sup>-</sup> availability at plasma membrane inner and outer surfaces. Hydration of CO<sub>2</sub> by CAs determines local HCO<sub>3</sub><sup>-</sup> concentration both at the outer and inner plasma membrane surfaces (102). Several CAs are localized in the cytoplasm (such as CA2 and CA7) and several are anchored at the plasma membrane (such as CA4, CA12 and CA14) with the catalytic site at the extracellular surface and regulate HCO<sub>3</sub><sup>-</sup> concentration at the basolateral (CA4 and CA12), or the luminal (CA4) membrane surfaces (33).

CAs localized in the plasma membrane and cytoplasm interact with H<sup>+</sup> and HCO<sub>3</sub><sup>-</sup> transporters that mediate ductal fluid and HCO<sub>3</sub><sup>-</sup> secretion and regulate their activity. CA4 interacts with the C

terminus of NBCe1-A to increase its activity (6). The C terminus of NBCe1-A and NBCe1-B are conserved and thus it is likely that CA4 regulates NBCe1-B. NBCn1-A recruits the cytoplasmic CA2 to the plasma membrane, where CA2 increases the activity of NBCn1-A (95). CA2 is closely associated with NHE3 and increases NHE3 activity (80). CA2 interacts with a novel site at the C terminus of NHE1 to regulate NHE1 activity (89). CA2 has been reported to interact with the C terminus of slc26a6 to increase its activity. However, the role of other CAs, in particular the plasma membrane anchored CAs, on the activity of the slc26a6 and other SLC26 transporters has not been investigated yet. Finally, CA2 also interacts with AQP1 to increase water flux by AQP1 by an unknown mechanism (158). A particularly interesting CA is the basolateral membrane anchored CA12 with its catalytic site at the extracellular membrane surface. A human mutation in CA12(E143K) is the cause of an autosomal recessive form of salt wasting, which leads to hyponatremia with hyperkalemia, high sweat Cl<sup>-</sup>, dehydration and failure to thrive. (31, 32, 106). A recent work to understand the cause of the disease established a prominent role for CA12 in ductal fluid and HCO<sub>3</sub><sup>-</sup> secretion. Thus, CA12 increased, while CA12 (E143K) markedly reduced ductal fluid secretion in isolated ducts and *in vivo*. This could be attributed to a potent stimulation of ductal and topically expressed AE2 by CA12 (53). The E143K mutation is a folding mutation that resulted in retention of CA12(E143K) in the ER (53). How exactly CA12 with an external catalytic site activates AE2 is not obvious. CA12 may clear the extruded HCO<sub>3</sub><sup>-</sup> from the membrane surface to prevent its buildup at the mouth of the AE2. If this can be established, it will be a new mode of regulating HCO<sub>3</sub><sup>-</sup> transporters by CAs.

## **IV. Regulation and Mechanism of Pancreatic HCO<sub>3</sub><sup>-</sup> Secretion**

### **A. Intracellular Signaling Pathways: cAMP and Ca<sup>2+</sup>**

The cAMP/PKA pathway is central in inducing ductal  $\text{HCO}_3^-$  secretion. Secretin is the major hormone that activates the cAMP pathway. VIP also signals to increase cAMP via VIP receptors (VPAC1) (30, 152). At maximal receptor stimulation, the cAMP/PKA pathway can fully activate fluid and  $\text{HCO}_3^-$  secretion by activation of the apical CFTR and the basolateral  $\text{Na}^+$ - $\text{HCO}_3^-$  cotransporter, NBCe1-B (165). However, at physiological conditions the cAMP/PKA pathway synergizes with the  $\text{Ca}^{2+}$  signaling pathway to activate the secretory process (see below).

Several agonists that act on the pancreatic duct engage the  $\text{Ca}^{2+}$  signaling pathway. These include CCK, cholinergic stimuli, P2Rs, and protease-activated receptor 2 (PAR2) receptors (71, 124). When activated, the CCK and muscarinic receptors activate  $\text{PLC}\beta$  to generate  $\text{IP}_3$  that releases  $\text{Ca}^{2+}$  from intracellular stores, mainly the endoplasmic reticulum (ER) and activates the membrane  $\text{Ca}^{2+}$  influx channels, Orai and TRPC. P2Rs (96, 110) and PAR2 (8, 107, 109, 111) also act through activation of the  $\text{Ca}^{2+}$  signaling pathway. At physiological stimulus intensity, the cAMP and  $\text{Ca}^{2+}$  signaling pathways synergize to activate ductal secretion (67). Early studies *in vivo* already noted the synergistic action of ductal stimuli. Application of secretin at a level observed in the postprandial state only produces modest  $\text{HCO}_3^-$  and fluid output (28, 45). Application of CCK and stimulation of M1 and M3 receptors markedly augmented secretin-stimulated pancreatic fluid secretion, although alone CCK and muscarinic stimulation have minimal effect on ductal secretion (86, 167). The molecular mechanism of synergism was resolved with the discovery of regulation of ductal secretion by IRBIT which is discussed below. The cAMP and  $\text{Ca}^{2+}$  signaling pathways crosstalk on several additional levels to modulate the activity of each other (67, 121). cAMP/PKA phosphorylates  $\text{IP}_3\text{R2}$  to augment  $\text{Ca}^{2+}$  release from the ER (16).  $\text{Ca}^{2+}$  influx through the Orai1 channels activates the  $\text{Ca}^{2+}$ -dependent adenylyl cyclase (AC) AC8 (160).  $\text{Ca}^{2+}$  can also activate the CFTR-dependent  $\text{Cl}^-/\text{HCO}_3^-$  exchange activity in CAPAN-1 human

pancreatic duct cells (108), which may involve activation by IRBIT.

## B. Regulation by IRBIT


### *Activation of NBCe1-B, slc26a6, and CFTR*

IRBIT was isolated as a protein that interacts with the  $\text{IP}_3$  binding pocket of the receptors ( $\text{IP}_3\text{Rs}$ ) and it can be dissociated from the  $\text{IP}_3\text{Rs}$  by  $\text{IP}_3$  (25). IRBIT competes with  $\text{IP}_3$  for binding to the  $\text{IP}_3\text{Rs}$  (10) to inhibit  $\text{Ca}^{2+}$  release. In fact, the  $\text{IP}_3\text{Rs}$  appear to function as IRBIT buffers to prevent IRBIT access to many transporters and targets regulated by IRBIT (87). The C-terminal region of IRBIT family proteins shows ~ 50% homology with the ubiquitous housekeeping enzyme S-adenosyl-l-homocysteine hydrolase (AHCY), with IRBIT having additional N terminal sequence while it lacks the hydrolase activity (9). The main known domains of IRBIT are PP1 and calcineurin binding motif, a PEST domain, a coiled-coil domain, and a PDZ ligand at the end of C terminus (87, 153).

IRBIT plays an important role in pancreatic ductal secretion by regulating multiple transporters and mediating the synergistic action of the cAMP/PKA and  $\text{Ca}^{2+}$  signaling pathways (**Figure 2**). Knockdown of IRBIT in ducts and knockout in mice modestly inhibit fully stimulated pancreatic duct fluid and  $\text{HCO}_3^-$  secretion (165), and eliminates the physiological synergistic action of the cAMP/PKA and  $\text{Ca}^{2+}$  signaling pathways (122). IRBIT accumulates at the apical pole where  $\text{IP}_3\text{Rs}$  are highly expressed, but it can be found all over the cell where  $\text{IP}_3\text{Rs}$  are present (88). A search for IRBIT binding proteins identified NBCe1-B as a binding partner, where IRBIT binds to the N terminus autoinhibitory domain of NBCe1-B to activate it by removing the autoinhibition (143). Subsequent detailed studies, in particular with the pancreatic duct revealed that IRBIT at the apical pole potentially activates the apical CFTR (163, 165), SLC26A6 (122), and NHE3 (49). At the basal side, IRBIT regulates NBCe1-B (143, 163, 165). IRBIT activates the transporters by multiple mechanisms. First, IRBIT recruits protein phosphatase 1 (PP1)

to the transporters to dephosphorylate serine residue 75 in NBCe1-B and yet to be identified residue in CFTR that are phosphorylated by the kinase SPAK. For these phosphorylations SPAK must be activated by phosphorylated by the two kinases WNK1 and/or WNK4 (138). IRBIT also recruits the phosphatase calcineurin to dephosphorylate serine residue 12 that is phosphorylated by CaMKII (153). This enhances the plasma membrane relocation of NBCe1-B, CFTR (163) and slc26a6 (122) from intracellular vesicular pools. At the plasma membrane, IRBIT

directly interacts with the transporters to further increase their activity. Moreover, phosphorylation by SPAK and CaMKII and dephosphorylation by the respective phosphatases PP1 and calcineurin determines regulation of NBCe1-B, and likely other IRBIT-regulated transporters, by  $Cl_{in}^-$  (153). The mechanism by which IRBIT activates the other transporters is not known at this time beyond the need for the PDZ binding motif of IRBIT for assembling the IRBIT-NBCe1-B and IRBIT-CFTR complex (165).



**Figure 2.** A model for IRBIT associated pathway of pancreatic ductal fluid and  $HCO_3^-$  secretion. Key domains of IRBIT related to  $HCO_3^-$  secretion are illustrated at the top of the figure. In the resting state, IRBIT is bound to  $IP_3Rs$ , and SPAK phosphorylates NBCe1-B, SLC26A6, and CFTR located at intracellular organelle. When the duct cells are stimulated,  $IP_3$  is released and bound to  $IP_3Rs$ , while IRBIT is disengaged from  $IP_3Rs$ . PP1 recruited to IRBIT dephosphorylates transporters located at the plasma membrane. IRBIT also binds to the autoinhibitory domain of NBCe1-B to activate it. Increased surface expression of the transporters also aids pancreatic ductal  $HCO_3^-$  secretion. Modified from (121). See text for details.

## *IRBIT and Synergism*

An important action of IRBIT is mediating the synergistic action of the cAMP/PKA and  $\text{Ca}^{2+}$  signaling pathways (122) (see **Figure 2**). Physiological stimulus intensity must be quite weak to prevent cell toxicity that occurs under strong stimulation of all signaling pathways. Indeed, at physiological stimulus intensity the secretory process is activated only by about 5-10% or less of maximal stimulation. Synergism between weakly stimulated signaling is used to generate the maximal response while avoiding cell toxicity and increasing fidelity. IRBIT mediates the synergism between the cAMP/PKA and  $\text{Ca}^{2+}$  signaling pathways by translocation between cellular compartments and transporters. At the resting state, IRBIT is sequestered by the high level of  $\text{IP}_3\text{Rs}$  at the ductal ER apical pole and is not available for interaction with the transporters. The affinity of the  $\text{IP}_3\text{Rs}$  for IRBIT and  $\text{IP}_3$  is regulated by PKA-mediated phosphorylation of specific  $\text{IP}_3\text{Rs}$  serine residues. Phosphorylation of the serine residues increases the affinity for  $\text{IP}_3$  and at the same time decreases the affinity for IRBIT. Now, a small increase in  $\text{IP}_3$  evoked by weak stimulation of the  $\text{Ca}^{2+}$  signaling pathway is sufficient to dissociate IRBIT from the  $\text{IP}_3\text{Rs}$  (122). The released IRBIT can bind to CFTR and *slc26a6* first in intracellular vesicles to dephosphorylate them by the IRBIT-recruited PP1 and calcineurin and promote their translocation to the luminal membrane. At the luminal membrane, IRBIT activates the transporters and reduce their inhibition by  $\text{Cl}^-_{\text{in}}$  to initiate ductal fluid and  $\text{HCO}_3^-$  secretion (122, 153). Of note, the synergistic action of the cAMP/PKA and  $\text{Ca}^{2+}$  signaling pathways is eliminated by the knockout of IRBIT (122), highlighting the key role of IRBIT in the synergistic action of the cAMP/PKA and  $\text{Ca}^{2+}$  signaling pathways, which is the physiological way that ductal fluid and  $\text{HCO}_3^-$  secretion take place.

### **C. Regulation by $[\text{Cl}^-]_i$**

#### *WNK1 and dynamic regulation of CFTR $\text{HCO}_3^-$*


## *permeability*

The WNK proteins consist of four members (WNK1 – WNK4) with a conserved kinase domain that is noted for the unique position of the catalytic lysine residue (105). The discovery that mutations in WNK1 and WNK4 cause hypertension in humans has attracted much attention to these kinases function and regulation (161). The main function of the WNKs is the regulation of  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Cl}^-$ ,  $\text{HCO}_3^-$ , and  $\text{Ca}^{2+}$  transporters in epithelia and brain (34, 54, 55, 121). The WNKs act either by regulating surface expression of membrane transporters through modulation of their endocytosis or by phosphorylating the transporters and other target proteins directly or indirectly through affecting the effect of other kinases (55). Several functions of WNKs are mediated by phosphorylating and activating the downstream oxidative stress-responsive kinase 1 (OSR1) and SPAK (26). WNK1, WNK3, WNK4, SPAK, and OSR1 are expressed in the pancreatic duct (119, 163) and participate in the regulation of  $\text{HCO}_3^-$  transporters and channels (87). Accordingly, knockdown of WNK4 alone or a combined knockdown of WNK1, WNK3 and WNK4 increase pancreatic duct fluid secretion by removing a tonic negative effect on ductal  $\text{HCO}_3^-$  transporters (163). However, the role of the WNKs, in particular WNK1, changes at the terminal portion on the duct when  $[\text{Cl}^-]_i$  is reduced to below 10 mM. WNK1 and the other WNKs, binds  $[\text{Cl}^-]_i$  and their activity is regulated by  $[\text{Cl}^-]_i$  (125, 141, 151).

The role of WNK1 in pancreatic  $\text{HCO}_3^-$  secretion is illustrated in the left portion of **Figure 3**. Osmotic stress or low  $[\text{Cl}^-]_i$  activates WNK1 (125). Notably, activation of WNK1 by low  $[\text{Cl}^-]_i$  greatly increases the  $\text{HCO}_3^-$  permeability of CFTR (66, 119). During active pancreatic  $\text{HCO}_3^-$  secretion, lower  $\text{Cl}^-$  concentration in the pancreatic juice progressively reduces  $\text{Cl}^-$  absorption. Because of the low basolateral and high luminal  $\text{Cl}^-$  permeability (58, 119),  $[\text{Cl}^-]_i$  rapidly decreases in response to the reduction in luminal duct  $\text{Cl}^-$  concentration. At a membrane potential of -60 mV,  $[\text{Cl}^-]_i$  is less than

1/10 of luminal  $\text{Cl}^-$  concentration. Indeed, ductal  $[\text{Cl}^-]_i$  was estimated to be about 5 mM during

cAMP-induced active secretion (58, 119).




**Figure 3.** A model depicting WNK1-mediated regulation of CFTR in pancreatic ductal function. During active pancreatic  $\text{HCO}_3^-$  secretion,  $\text{Cl}^-$  concentration in the pancreatic juice is progressively reduced due to  $\text{Cl}^-/\text{HCO}_3^-$  exchange activities at the apical membrane of duct cells. Because the basolateral membrane of duct cells has poor  $\text{Cl}^-$  permeability but the apical  $\text{Cl}^-$  permeability is very high due to activation of CFTR,  $[\text{Cl}^-]_i$  rapidly decreases in response to the reduction in luminal  $\text{Cl}^-$  concentration. Activation of WNK1 by low  $[\text{Cl}^-]_i$  increases the  $P_{\text{HCO}_3^-}/P_{\text{Cl}^-}$  of CFTR to over 1.0, which greatly augments  $\text{HCO}_3^-$  flux through the CFTR pore. Simultaneously, WNK1/SPAK pathway inhibits Slc26a6 to prevent  $\text{HCO}_3^-$  reabsorption. This mechanism enables an increase to as much as 140 mM  $\text{HCO}_3^-$  in pancreatic juice. See text for details. Modified from (87).

WNK1 modulates the anion selectivity of CFTR by changing its pore size (66). Stimulation by WNK1 increases CFTR pore size from 4.8 Å to 5.3 Å, which facilitates the passage of  $\text{HCO}_3^-$ . (4.3 Å, diameter), more than the smaller anion,  $\text{Cl}^-$  (3.7 Å,

diameter). Changes in pore size affect the energy barrier of ion dehydration by altering the electric permittivity of the water-filled cavity in the pore. Dielectric constant (relative permittivity,  $\epsilon$ ) is a unit of electric permittivity, and the dielectric constant of

water ( $\epsilon_w$ ) is approximately 80 at room temperature. Water molecules in confined geometry like ion channels exhibit a space-dependent reduction in the pore water  $\epsilon_w$  down to 20, due to the restriction of the translational and rotational mobility of water molecules (2). Pore dilation relieves this restriction of water molecule movement and increases  $\epsilon_w$ , which eventually leads to an increase in the overall  $\epsilon$  of the anion channel pore. Indeed, the pore dilation induced by WNK1 activation increased the  $\epsilon$  of the CFTR pore from 16 to 43 (66). In general, ions pass through the channel after dehydration (at least partial dehydration). Asymmetrically charged ions, such as  $\text{HCO}_3^-$ , show lower permeability than the symmetrically charged ions, such as  $\text{Cl}^-$ , due to

the high hydration/dehydration energy barrier. The increase in anion channel pore  $\epsilon$  greatly alleviates the dehydration penalty of the asymmetrically charged  $\text{HCO}_3^-$  and increases  $P_{\text{HCO}_3^-}/P_{\text{Cl}^-}$  (**Figure 4**). In an initial study, WNK-OSR1 or WNK1-SPAK complex was suggested to increase the CFTR  $P_{\text{HCO}_3^-}/P_{\text{Cl}^-}$  (119). However subsequent study showed that WNK1 alone was sufficient to increase CFTR  $P_{\text{HCO}_3^-}/P_{\text{Cl}^-}$  (70). Molecular dissection of the WNK1 domains revealed that the WNK1 kinase domain is responsible for CFTR  $P_{\text{HCO}_3^-}/P_{\text{Cl}^-}$  selectivity by direct association with CFTR, while the surrounding N-terminal regions mediate the  $[\text{Cl}^-]_i$ -sensitivity of WNK1 (70).




**Figure 4.** WNK1 modulates the anion selectivity of CFTR by changing the pore size. Stimulation by WNK1 increases the pore size of CFTR from 4.8 Å to 5.3 Å and the pore dilation increases the dielectric constant ( $\epsilon$ ) of the CFTR pore from 16 to 43. The increase in pore size facilitates the passage of the larger anion,  $\text{HCO}_3^-$  (4.3 Å, diameter), more than the smaller anion,  $\text{Cl}^-$  (3.7 Å, diameter) by reducing the energy barriers of size-exclusion. More importantly, the dielectric constant increase enhances the  $\text{HCO}_3^-$  permeability of CFTR by reducing energy barriers required for ion dehydration of  $\text{HCO}_3^-$  (66). See text for details.

Although the precise WNK1-binding sites on the CFTR are not fully defined, examining pancreatitis-causing CFTR mutations revealed that R74 and R75 located in the first elbow helix region of the CFTR, are involved in the WNK1-CFTR

association [39]. A computational protein-protein docking analysis using the Protein Data Bank-deposited structures of human CFTR and the WNK1 kinase domain showed that WNK1 S231–T234 and I384–E388 can potentially bind to an

intracellular CFTR region near R74–R75 in the elbow helix 1 (**Figure 5**). The handle-like elbow helix 1 is located immediately ahead of transmembrane domain 1 and contacts a proximally located lasso motif that has been suggested to play a role in CFTR gating and regulation of the R domain (93). Therefore, it appears that the binding of WNK1 kinase domain to the elbow helix 1 region of CFTR affects the

CFTR open structure to facilitate  $\text{HCO}_3^-$  permeation (142). Notably, WNK1 not only increases  $P_{\text{HCO}_3^-}/P_{\text{Cl}^-}$  of CFTR  $\text{HCO}_3^-$  channel but the  $\text{HCO}_3^-$  conductance ( $G_{\text{HCO}_3^-}$ ) and  $P_o$  in single channel recording (70). Increase in CFTR  $G_{\text{HCO}_3^-}$  may also significantly contribute to augmenting  $\text{HCO}_3^-$  flux across the apical membrane of pancreatic duct cells.



**Figure 5.** Structural model for the molecular complex between hCFTR and the WNK1 kinase domain in the presence of a lipid bilayer. The R74 (yellow balls) and R75 (orange balls) residues from hCFTR participate in the binding interface. The figure shows the hCFTR-WNK1 complex predicted by ClusPro, after equilibration in the MD simulation system where it is embedded into the membrane lipids (lines with their phosphorus atoms shown as purple spheres) and solvated by 0.1 M NaCl solution. The snapshot was taken after 100 ns MD simulations. The inset figure shows a close-up view of interfacial interactions. WNK1 residues at the interface include S231, K233, T234, T386, and E388. Modified from (70).

Interestingly, activated WNK1 while increasing CFTR  $P_{\text{HCO}_3^-}/P_{\text{Cl}^-}$  and  $G_{\text{HCO}_3^-}$ , does not lose the inhibitory effect on SLC26A6 and SLC26A3 (119).

When the luminal  $\text{HCO}_3^-$  concentration is greater than 140 mM, continuous activation of apical  $\text{Cl}^-/\text{HCO}_3^-$  exchange would reverse to absorb  $\text{HCO}_3^-$ .

from the lumen. This is more of a problem for the  $2\text{Cl}^-/1\text{HCO}_3^-$  exchange by *slc26a3* and less, if at all, for the  $1\text{Cl}^-/2\text{HCO}_3^-$  *slc26a6*, especially at membrane potential of -60 mV across the luminal membrane. However, inhibition of the apical  $\text{Cl}^-/\text{HCO}_3^-$  exchangers is required to prevent the reverse mode of  $\text{Cl}^-/\text{HCO}_3^-$  exchange activity if *slc26a3* dominates the exchange when ductal  $[\text{Cl}^-]_i$  is below 10 mM and ultimately achieves  $\text{HCO}_3^-$  concentration above 140 mM in pancreatic juice (146, 148).

#### *Cl<sub>in</sub> as a signaling ion, the case for NBCe1-B*

$[\text{Cl}^-]_i$  emerged as a signaling ion by regulating several ion transporters and channels. A comprehensive review of  $\text{Cl}^-$  as a *bona fide* signaling ion can be found in (97). Here we discuss the signaling function of  $\text{Cl}^-_{in}$  with respect to ductal function. By virtue of regulating the function of the WNK kinases  $[\text{Cl}^-]_i$  may affect other transporters regulated by these kinases. A significant discovery is that  $[\text{Cl}^-]_i$  profoundly regulates the activity of several  $\text{Na}^+-\text{HCO}_3^-$  cotransporters (NBCs) at the  $[\text{Cl}^-]_i$  physiological range (138, 153).  $[\text{Cl}^-]_i$  regulates the activity of all NBCs tested NBCe1-B, NBCe1-C, and NBCe1-A. The IRBIT-independent activity of NBCe1-B is inhibited by  $[\text{Cl}^-]_i$  between 60-140 mM that is outside the physiological range and may function to inhibit NBCe1-B activity under pathological conditions. Most notably, when activated by IRBIT, NBCe1-B activity is reduced by  $[\text{Cl}^-]_i$  in the range of 5-20 mM, where at 20 mM  $[\text{Cl}^-]_i$ , NBCe1-B activity is reduced to the basal, IRBIT-independent level. Molecular analysis identified two  $\text{Cl}^-$  interacting motifs at the N terminus of NBCe1-B that mediate high and low affinity inhibition by  $[\text{Cl}^-]_i$ . Regulation of NBCe1-B is mediated by sites that contain the GXXXP motif. The first site mediates the high  $[\text{Cl}^-]_i$  affinity (5-20 mM) regulation of NBCe1-B and the second site mediates the low  $[\text{Cl}^-]_i$  affinity (60-140 mM) regulation of NBCe1-B (138). NBCe1-C activity is not regulated by IRBIT and in this case regulation of NBCe1-C is mediated by a single site containing the GXXXP motif and takes place at  $[\text{Cl}^-]_i$  between

10-30 mM. Regulation of NBCe1-A by  $[\text{Cl}^-]_i$  is mediated by a cryptic  $\text{Cl}^-$  interacting site containing the GXXXP motif. The cryptic NBCe1-A  $[\text{Cl}^-]_i$  interacting sites was unmasked by deletion of residues 29-41. Further analysis showed that interaction of  $\text{Cl}^-_{in}$  with the GXXXP sites is regulated by phosphorylation/dephosphorylation events with SPAK and PP1 acting on serine 65 to affect  $\text{Cl}^-$  sensing by the  $^{32}\text{GXXXP}^{36}$  site, while CaMKII and calcineurin acting on serine 12 to affect  $\text{Cl}^-$  sensing by the  $^{194}\text{GXXXP}^{198}$  site (153). Other phosphorylation sites affecting NBCe1-B activity are Ser232, Ser233, and Ser235 with the phosphorylation status of Ser232, Ser233, and Ser235 is regulated by IRBIT to determine whether NBCe1 transporters are in active or inactive conformations (153).

Hence, cells have a  $[\text{Cl}^-]_i$  sensing mechanism that plays an important role in the regulation of  $\text{Na}^+$  and  $\text{HCO}_3^-$  transporters that mediate the critical step of  $\text{HCO}_3^-$  influx in the process of ductal fluid and  $\text{HCO}_3^-$  secretion. At  $[\text{Cl}^-]_i$  of up to 20 mM, CFTR functions mostly as a  $\text{Cl}^-$  channel and *slc26a6* mediates most ductal  $\text{HCO}_3^-$  secretion. As  $[\text{Cl}^-]_i$  is reduced below 20 mM and additional  $\text{HCO}_3^-$  secretion takes place in the face of unfavorable  $\text{Cl}^-$  and  $\text{HCO}_3^-$  gradients across the apical membrane, there is an increased demand for  $\text{HCO}_3^-$  entry across the basolateral membrane. Pancreatic duct cells achieve this by  $[\text{Cl}^-]_i$ -mediated regulation of NBCe1-B and CFTR, at which NBCe1-B activity and CFTR  $\text{HCO}_3^-$  permeability gradually increase as  $[\text{Cl}^-]_i$  is reduced towards 5 mM.

#### **D. A Model for Pancreatic $\text{HCO}_3^-$ Secretion**

Electrogenic  $\text{HCO}_3^-$  transporters can generate higher gradients of  $\text{HCO}_3^-$  than electroneutral transporters when the electro-repulsive force generated by the negative membrane potential is coupled to the basolateral uptake of  $\text{HCO}_3^-$  by NBCe1-B and the luminal efflux of  $\text{HCO}_3^-$  through SLC26A6 and CFTR. The electrogenic SLC26A6 exchanger with the stoichiometry of  $1\text{Cl}^-:2\text{HCO}_3^-$ , can achieve luminal  $\text{HCO}_3^-$  concentration of up to

about 120 mM at apical membrane potential of -60 mV (148). To drive luminal  $\text{HCO}_3^-$  concentration to 140 mM, the physiologic  $\text{HCO}_3^-$  concentrations in pancreatic juice, another mechanism is needed (148). Such a mechanism should be  $\text{Cl}^-$  independent, since significant fraction of pancreatic  $\text{HCO}_3^-$  secretion is retained in the absence of luminal  $\text{Cl}^-$  (59, 61). The WNK1 activated CFTR satisfy these requirements. At  $\text{HCO}_3^-_{\text{in}}$  in stimulated duct cells above 25 mM and membrane potential of -60 mV, CFTR mediates  $\text{HCO}_3^-$  efflux even at luminal  $\text{HCO}_3^-$  concentrations of above 140 mM. Transport by NBCe1-B and *slc26a6* results in osmotic transport of  $\text{HCO}_3^-$  that is essential for the transcellular water transport by the duct. The transcellular basal to luminal electrogenic  $\text{HCO}_3^-$  transport by both *slc26a6* and CFTR generates a lumen-negative electrical potential that results in paracellular  $\text{Na}^+$  secretion. Water flows down the osmotic gradient generated by the  $\text{Na}^+$  and  $\text{HCO}_3^-$  fluxes via paracellular and transcellular (aquaporins) pathways (**Figure 3**). Overall, these processes generate an efficient mechanism for  $\text{HCO}_3^-$ -driven ductal fluid secretion to generate the volume and  $\text{HCO}_3^-$  content of the pancreatic juice.

## V. Conclusions

The mechanism by which the human pancreatic duct secretes nearly isotonic  $\text{HCO}_3^-$  solution has long been an enigmatic question for both physiologists and clinicians (86, 148). When Bayliss and Starling first noticed that the exocrine pancreas secretes alkaline fluid, they assumed that carbonate is responsible for the strong alkalinity of the pancreatic juice (13). Later, with better understanding of the carbonate/ $\text{HCO}_3^-$ / $\text{CO}_2$  buffer system (51), it became clear that the exocrine pancreas secretes fluid in which the dominant anion is  $\text{HCO}_3^-$ , and  $\text{HCO}_3^-$  secretion is coupled to fluid secretion (19, 28, 46). Current

understanding indicates that activation of three key transporters, the basolateral NBCe1-B (and likely AE2), and the luminal SLC26A6 and CFTR, and their synergistic regulation by the cAMP and  $\text{Ca}^{2+}$  signaling pathways through IRBIT and WNK1 perform vectorial pancreatic  $\text{HCO}_3^-$  secretion that drives fluid secretion. NBCe1-B, with a 1  $\text{Na}^+$ /2  $\text{HCO}_3^-$  stoichiometry, is the main  $\text{HCO}_3^-$  concentrating transporter in the basolateral membrane, and can achieve the necessary  $\text{HCO}_3^-$  influx (1, 60, 172). Basolateral AE2 activity is also required to support ductal  $\text{HCO}_3^-$  fluid and  $\text{HCO}_3^-$  secretion probably by controlling cytoplasmic and near membrane  $\text{pH}_i$ , although the exact role of AE2 is not known at present. The electrogenic SLC26A6, with a 1  $\text{Cl}^-$ /2  $\text{HCO}_3^-$  stoichiometry is the major apical  $\text{Cl}^-$ / $\text{HCO}_3^-$  exchanger, which mediates most  $\text{HCO}_3^-$  efflux in the early step of pancreatic  $\text{HCO}_3^-$  secretion (76, 94). Activated WNK1 increases  $\text{HCO}_3^-$  permeability and conductance of CFTR, allowing further apical  $\text{HCO}_3^-$  efflux and setting the pancreatic juice  $\text{HCO}_3^-$  concentrations above 140 mM (119). Ductal fluid and  $\text{HCO}_3^-$  secretion is essential for the function of the pancreas and is severely altered in all form of pancreatitis (50, 168). Our understanding of the mechanism of pancreatic fluid and  $\text{HCO}_3^-$  secretion will continue to improve as our knowledge of existing pathways increases and new mechanisms are identified and delineated, to provide a better scientific basis for therapeutic approaches to treat diseases like cystic fibrosis and acute and chronic pancreatitis.

## VI. Acknowledgements

We thank Dong-Su Jang for assistance in illustrations. This work was supported by grant, 2013R1A3A2042197, from the National Research Foundation, the Ministry of Science, ICT & Future Planning, Republic of Korea and by Intramural NIH/NIDCR grant DE000735-010.

## VII. References

1. **Abuladze N, Lee I, Newman D, Hwang J, Boorer K, Pushkin A, and Kurtz I.** Molecular cloning, chromosomal localization, tissue distribution, and functional expression of the human pancreatic sodium bicarbonate cotransporter. *J Biol Chem* 273: 17689-17695, 1998. [PMID: 9651366](#).
2. **Aguilera-Arzo M, Andrio A, Aguilera VM, and Alcaraz A.** Dielectric saturation of water in a membrane protein channel. *Phys Chem Chem Phys* 11: 358-365, 2009. [PMID: 19088992](#).
3. **Ahn W, Kim KH, Lee JA, Kim JY, Choi JY, Moe OW, Milgram SL, Muallem S, and Lee MG.** Regulatory interaction between the cystic fibrosis transmembrane conductance regulator and HCO<sub>3</sub><sup>-</sup> salvage mechanisms in model systems and the mouse pancreatic duct. *J Biol Chem* 276: 17236-17243, 2001. [PMID: 11278980](#).
4. **Ahuja M, Chung WY, Lin WY, McNally BA, and Muallem S.** Ca<sup>2+</sup> Signaling in Exocrine Cells. *Cold Spring Harb Perspect Biol* 12: 2020. [PMID: 31636079](#).
5. **Almassy J, Diszhazi G, Skaliczki M, Marton I, Magyar ZE, Nanasi PP, and Yule DI.** Expression of BK channels and Na<sup>(+)</sup>-K<sup>(+)</sup> pumps in the apical membrane of lacrimal acinar cells suggests a new molecular mechanism for primary tear-secretion. *Ocul Surf* 17: 272-277, 2019. [PMID: 30685438](#).
6. **Alvarez BV, Loiselle FB, Supuran CT, Schwartz GJ, and Casey JR.** Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. *Biochemistry* 42: 12321-12329, 2003. [PMID: 14567693](#).
7. **Alvarez BV, Vithana EN, Yang Z, Koh AH, Yeung K, Yong V, Shandro HJ, Chen Y, Kolatkar P, Palasingam P, Zhang K, Aung T, and Casey JR.** Identification and characterization of a novel mutation in the carbonic anhydrase IV gene that causes retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 48: 3459-3468, 2007. [PMID: 17652713](#).
8. **Alvarez C, Regan JP, Merianos D, and Bass BL.** Protease-activated receptor-2 regulates bicarbonate secretion by pancreatic duct cells in vitro. *Surgery* 136: 669-676, 2004. [PMID: 15349117](#).
9. **Ando H, Kawaai K, and Mikoshiba K.** IRBIT: a regulator of ion channels and ion transporters. *Biochim Biophys Acta* 1843: 2195-2204, 2014. [PMID: 24518248](#).
10. **Ando H, Mizutani A, Matsu-ura T, and Mikoshiba K.** IRBIT, a novel inositol 1,4,5-trisphosphate (IP<sub>3</sub>) receptor-binding protein, is released from the IP<sub>3</sub> receptor upon IP<sub>3</sub> binding to the receptor. *J Biol Chem* 278: 10602-10612, 2003. [PMID: 112525476](#).
11. **Aoun J, Hayashi M, Sheikh IA, Sarkar P, Saha T, Ghosh P, Bhowmick R, Ghosh D, Chatterjee T, Chakrabarti P, Chakrabarti MK, and Hoque KM.** Anoctamin 6 Contributes to Cl<sup>-</sup> Secretion in Accessory Cholera Enterotoxin (Ace)-stimulated Diarrhea: AN ESSENTIAL ROLE FOR PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE (PIP<sub>2</sub>) SIGNALING IN CHOLERA. *J Biol Chem* 291: 26816-26836, 2016. [PMID: 27799301](#).
12. **Argent BE, and Case RM.** Pancreatic ducts. Cellular mechanism and control of bicarbonate secretion. *Physiology of the gastrointestinal tract* 1473-1497, 1994.
13. **Bayliss WM, and Starling EH.** The mechanism of pancreatic secretion. *J Physiol* 28: 325-353, 1902. [PMID: 16992627](#).
14. **Boron WF, Chen L, and Parker MD.** Modular structure of sodium-coupled bicarbonate transporters. *J Exp Biol* 212: 1697-1706, 2009. [PMID: 19448079](#).
15. **Brooks AM, and Grossman MI.** Postprandial pH and neutralizing capacity of the proximal duodenum in dogs. *Gastroenterology* 59: 85-89, 1970. [PMID: 5426993](#).
16. **Bruce JI, Shuttleworth TJ, Giovannucci DR, and Yule DI.** Phosphorylation of inositol 1,4,5-trisphosphate receptors in parotid acinar cells. A mechanism for the synergistic effects of cAMP on Ca<sup>2+</sup> signaling. *J Biol Chem* 277: 1340-1348, 2002. [PMID: 11694504](#).
17. **Burghardt B, Elkaer ML, Kwon TH, Racz GZ, Varga G, Steward MC, and Nielsen S.** Distribution of aquaporin water channels AQP1 and AQP5 in the ductal system of the human pancreas. *Gut* 52: 1008-1016, 2003. [PMID: 12801959](#).
18. **Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeiffer U, Ravazzolo R, Zegarra-Moran O, and Galletta LJ.** TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. *Science* 322: 590-594, 2008. [PMID: 18772398](#).
19. **Case RM, Harper AA, and Scratcherd T.** The secretion of electrolytes and enzymes by the pancreas of the anaesthetized cat. *J Physiol* 201: 335-348, 1969. [PMID: 5780548](#).
20. **Catalan MA, Nakamoto T, Gonzalez-Begne M, Camden JM, Wall SM, Clarke LL, and Melvin JE.** Cftr and ENaC ion channels mediate NaCl absorption in the mouse submandibular gland. *J Physiol* 588: 713-724, 2010. [PMID: 20026617](#).

21. **Chandra R, and Liddle RA.** Regulation of Pancreatic Secretion. *The Pancreapedia: Exocrine Pancreas Knowledge Base* 2015. [DOI: 10.3998/panc.2015.38](https://doi.org/10.3998/panc.2015.38).
22. **Chey WY, Lee YH, Hendricks JG, Rhodes RA, and Tai HH.** Plasma secretin concentrations in fasting and postprandial state in man. *Am J Dig Dis* 23: 981-988, 1978. [PMID: 31087](https://pubmed.ncbi.nlm.nih.gov/31087/).
23. **Choi JY, Muallem D, Kiselyov K, Lee MG, Thomas PJ, and Muallem S.** Aberrant CFTR-dependent HCO<sub>3</sub><sup>-</sup> transport in mutations associated with cystic fibrosis. *Nature* 410: 94-97, 2001. [PMID: 11242048](https://pubmed.ncbi.nlm.nih.gov/11242048/).
24. **Deeley RG, Westlake C, and Cole SP.** Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. *Physiol Rev* 86: 849-899, 2006. [PMID: 16816140](https://pubmed.ncbi.nlm.nih.gov/16816140/).
25. **Dekker JW, Budhia S, Angel NZ, Cooper BJ, Clark GJ, Hart DN, and Kato M.** Identification of an S-adenosylhomocysteine hydrolase-like transcript induced during dendritic cell differentiation. *Immunogenetics* 53: 993-1001, 2002. [PMID: 11904675](https://pubmed.ncbi.nlm.nih.gov/11904675/).
26. **Delpire E, and Gagnon KB.** SPAK and OSR1: STE20 kinases involved in the regulation of ion homeostasis and volume control in mammalian cells. *Biochem J* 409: 321-331, 2008. [PMID: 18092945](https://pubmed.ncbi.nlm.nih.gov/18092945/).
27. **Domschke S, Domschke W, Rosch W, Konturek SJ, Sprugel W, Mitznegg P, Wunsch E, and Demling L.** Inhibition by somatostatin of secretin-stimulated pancreatic secretion in man: a study with pure pancreatic juice. *Scand J Gastroenterol* 12: 59-63, 1977. [PMID: 189382](https://pubmed.ncbi.nlm.nih.gov/189382/).
28. **Domschke S, Domschke W, Rosch W, Konturek SJ, Wunsch E, and Demling L.** Bicarbonate and cyclic AMP content of pure human pancreatic juice in response to graded doses of synthetic secretin. *Gastroenterology* 70: 533-536, 1976. [PMID: 176080](https://pubmed.ncbi.nlm.nih.gov/176080/).
29. **Dorwart MR, Shcheynikov N, Yang D, and Muallem S.** The solute carrier 26 family of proteins in epithelial ion transport. *Physiology (Bethesda)* 23: 104-114, 2008. [PMID: 18400693](https://pubmed.ncbi.nlm.nih.gov/18400693/).
30. **Evans RL, Perrott MN, Lau KR, and Case RM.** Elevation of intracellular cAMP by noradrenaline and vasoactive intestinal peptide in striated ducts isolated from the rabbit mandibular salivary gland. *Arch Oral Biol* 41: 689-694, 1996. [PMID: 9015570](https://pubmed.ncbi.nlm.nih.gov/9015570/).
31. **Feinstein Y, Yerushalmi B, Loewenthal N, Alkrinawi S, Birk OS, Parvari R, and Hershkovitz E.** Natural history and clinical manifestations of hyponatremia and hyperchlorhidrosis due to carbonic anhydrase XII deficiency. *Horm Res Paediatr* 81: 336-342, 2014. [PMID: 24714577](https://pubmed.ncbi.nlm.nih.gov/24714577/).
32. **Feldshtein M, Elkrinawi S, Yerushalmi B, Marcus B, Vullo D, Romi H, Ofir R, Landau D, Sivan S, Supuran CT, and Birk OS.** Hyperchlorhidrosis caused by homozygous mutation in CA12, encoding carbonic anhydrase XII. *Am J Hum Genet* 87: 713-720, 2010. [PMID: 21035102](https://pubmed.ncbi.nlm.nih.gov/21035102/).
33. **Frost SC.** Physiological functions of the alpha class of carbonic anhydrases. *Subcell Biochem* 75: 9-30, 2014. [PMID: 24146372](https://pubmed.ncbi.nlm.nih.gov/24146372/).
34. **Furusho T, Uchida S, and Sohara E.** The WNK signaling pathway and salt-sensitive hypertension. *Hypertens Res* 43: 733-743, 2020. [PMID: 32286498](https://pubmed.ncbi.nlm.nih.gov/32286498/).
35. **Gagnon KB, and Delpire E.** Molecular physiology of SPAK and OSR1: two Ste20-related protein kinases regulating ion transport. *Physiol Rev* 92: 1577-1617, 2012. [PMID: 23073627](https://pubmed.ncbi.nlm.nih.gov/23073627/).
36. **Gautam D, Han SJ, Heard TS, Cui Y, Miller G, Bloodworth L, and Wess J.** Cholinergic stimulation of amylase secretion from pancreatic acinar cells studied with muscarinic acetylcholine receptor mutant mice. *J Pharmacol Exp Ther* 313: 995-1002, 2005. [PMID: 15764735](https://pubmed.ncbi.nlm.nih.gov/15764735/).
37. **Gerolami A, Marteau C, Matteo A, Sahel J, Portugal H, Pauli AM, Pastor J, and Sarles H.** Calcium carbonate saturation in human pancreatic juice: possible role of ductal H<sup>+</sup> secretion. *Gastroenterology* 96: 881-884, 1989. [PMID: 2914648](https://pubmed.ncbi.nlm.nih.gov/2914648/).
38. **Gray MA, Greenwell JR, Garton AJ, and Argent BE.** Regulation of maxi-K<sup>+</sup> channels on pancreatic duct cells by cyclic AMP-dependent phosphorylation. *J Membr Biol* 115: 203-215, 1990. [PMID: 1695685](https://pubmed.ncbi.nlm.nih.gov/1695685/).
39. **Gray MA, Harris A, Coleman L, Greenwell JR, and Argent BE.** Two types of chloride channel on duct cells cultured from human fetal pancreas. *Am J Physiol* 257: C240-251, 1989. [PMID: 2475028](https://pubmed.ncbi.nlm.nih.gov/2475028/).
40. **Gray MA, Winpenny JP, Porteous DJ, Dorin JR, and Argent BE.** CFTR and calcium-activated chloride currents in pancreatic duct cells of a transgenic CF mouse. *Am J Physiol* 266: C213-221, 1994. [PMID: 7508188](https://pubmed.ncbi.nlm.nih.gov/7508188/).
41. **Gross E, Fedotoff O, Pushkin A, Abuladze N, Newman D, and Kurtz I.** Phosphorylation-induced modulation of pNBC1 function: distinct roles for the amino- and carboxy-termini. *J Physiol* 549: 673-682, 2003. [PMID: 12730338](https://pubmed.ncbi.nlm.nih.gov/12730338/).
42. **Gross E, Hawkins K, Abuladze N, Pushkin A, Cotton CU, Hopfer U, and Kurtz I.** The stoichiometry of the electrogenic sodium bicarbonate cotransporter NBC1 is cell-type dependent. *J Physiol* 531: 597-603, 2001. [PMID: 11251043](https://pubmed.ncbi.nlm.nih.gov/11251043/).
43. **Grundy D, Hutson D, and Scratcherd T.** The response of the pancreas of the anaesthetized cat to secretin before, during and after reversible vagal blockade. *J Physiol* 342: 517-526, 1983. [PMID: 6631748](https://pubmed.ncbi.nlm.nih.gov/6631748/).
44. **Guggino WB.** The cystic fibrosis transmembrane regulator forms macromolecular complexes with PDZ

- domain scaffold proteins. *Proc Am Thorac Soc* 1: 28-32, 2004. [PMID: 16113408](#).
45. **Gyr K, Beglinger C, Fried M, Grotzinger U, Kayasseh L, Stalder GA, and Girard J.** Plasma secretin and pancreatic response to various stimulants including a meal. *Am J Physiol* 246: G535-542, 1984. [PMID: 6720952](#).
  46. **Hart WM, and Thomas JE.** Bicarbonate and chloride of pancreatic juice secreted in response to various stimuli. *Gastroenterology* 4: 1945.
  47. **Hatefi Y, and Hanstein WG.** Solubilization of particulate proteins and nonelectrolytes by chaotropic agents. *Proc Natl Acad Sci U S A* 62: 1129-1136, 1969. [PMID: 5256411](#).
  48. **He P, Klein J, and Yun CC.** Activation of Na<sup>+</sup>/H<sup>+</sup> exchanger NHE3 by angiotensin II is mediated by inositol 1,4,5-triphosphate (IP3) receptor-binding protein released with IP3 (IRBIT) and Ca<sup>2+</sup>/calmodulin-dependent protein kinase II. *J Biol Chem* 285: 27869-27878, 2010. [PMID: 20584908](#).
  49. **He P, Zhang H, and Yun CC.** IRBIT, inositol 1,4,5-triphosphate (IP3) receptor-binding protein released with IP3, binds Na<sup>+</sup>/H<sup>+</sup> exchanger NHE3 and activates NHE3 activity in response to calcium. *J Biol Chem* 283: 33544-33553, 2008. [PMID: 18829453](#).
  50. **Hegy P, Wilschanski M, Muallem S, Lukacs GL, Sahin-Toth M, Uc A, Gray MA, Rakonczay Z, Jr., and Maleth J.** CFTR: A New Horizon in the Pathomechanism and Treatment of Pancreatitis. *Rev Physiol Biochem Pharmacol* 170: 37-66, 2016. [PMID: 26856995](#).
  51. **Henderson LJ.** The Regulation of Neutrality in the Animal Body. *Science* 37: 389-395, 1913. [PMID: 17795147](#).
  52. **Holst JJ, Fahrenkrug J, Knuhtsen S, Jensen SL, Poulsen SS, and Nielsen OV.** Vasoactive intestinal polypeptide (VIP) in the pig pancreas: role of VIPergic nerves in control of fluid and bicarbonate secretion. *Regul Pept* 8: 245-259, 1984. [PMID: 6379759](#).
  53. **Hong JH, Muhammad E, Zheng C, Hershkovitz E, Alkrinawi S, Loewenthal N, Parvari R, and Muallem S.** Essential role of carbonic anhydrase XII in secretory gland fluid and HCO<sub>3</sub><sup>-</sup> secretion revealed by disease causing human mutation. *J Physiol* 593: 5299-5312, 2015. [PMID: 26486891](#).
  54. **Huang CL, Cha SK, Wang HR, Xie J, and Cobb MH.** WNKs: protein kinases with a unique kinase domain. *Exp Mol Med* 39: 565-573, 2007. [PMID: 18059132](#).
  55. **Huang CL, Yang SS, and Lin SH.** Mechanism of regulation of renal ion transport by WNK kinases. *Curr Opin Nephrol Hypertens* 17: 519-525, 2008. [PMID: 18695394](#).
  56. **Hug MJ, Tamada T, and Bridges RJ.** CFTR and bicarbonate secretion by [correction of to] epithelial cells. *News Physiol Sci* 18: 38-42, 2003. [PMID: 12531931](#).
  57. **Ishiguro H, Naruse S, Kitagawa M, Hayakawa T, Case RM, and Steward MC.** Luminal ATP stimulates fluid and HCO<sub>3</sub><sup>-</sup> secretion in guinea-pig pancreatic duct. *J Physiol* 519 Pt 2: 551-558, 1999. [PMID: 10457070](#).
  58. **Ishiguro H, Naruse S, Kitagawa M, Mabuchi T, Kondo T, Hayakawa T, Case RM, and Steward MC.** Chloride transport in microperfused interlobular ducts isolated from guinea-pig pancreas. *J Physiol* 539: 175-189, 2002. [PMID: 11850511](#).
  59. **Ishiguro H, Naruse S, Steward MC, Kitagawa M, Ko SB, Hayakawa T, and Case RM.** Fluid secretion in interlobular ducts isolated from guinea-pig pancreas. *J Physiol* 511 ( Pt 2): 407-422, 1998. [PMID: 9706019](#).
  60. **Ishiguro H, Steward MC, Lindsay AR, and Case RM.** Accumulation of intracellular HCO<sub>3</sub><sup>-</sup> by Na(+)-HCO<sub>3</sub><sup>-</sup> cotransport in interlobular ducts from guinea-pig pancreas. *J Physiol* 495 ( Pt 1): 169-178, 1996. [PMID: 8866360](#).
  61. **Ishiguro H, Steward MC, Naruse S, Ko SB, Goto H, Case RM, Kondo T, and Yamamoto A.** CFTR functions as a bicarbonate channel in pancreatic duct cells. *J Gen Physiol* 133: 315-326, 2009. [PMID: 19204187](#).
  62. **Ishiguro H, Steward MC, Wilson RW, and Case RM.** Bicarbonate secretion in interlobular ducts from guinea-pig pancreas. *J Physiol* 495 ( Pt 1): 179-191, 1996. [PMID: 8866361](#).
  63. **Jha A, Chung WY, Vachel L, Maleth J, Lake S, Zhang G, Ahuja M, and Muallem S.** Anoctamin 8 tethers endoplasmic reticulum and plasma membrane for assembly of Ca(2+) signaling complexes at the ER/PM compartment. *EMBO J* 38: 2019. [PMID: 31061173](#).
  64. **Jin C, Naruse S, Kitagawa M, Ishiguro H, Nakajima M, Mizuno N, Ko SB, and Hayakawa T.** The effect of calcitonin gene-related peptide on pancreatic blood flow and secretion in conscious dogs. *Regul Pept* 99: 9-15, 2001. [PMID: 11257309](#).
  65. **Johansen PG, Anderson CM, and Hadorn B.** Cystic fibrosis of the pancreas. A generalised disturbance of water and electrolyte movement in exocrine tissues. *Lancet* 1: 455-460, 1968. [PMID: 4170642](#).
  66. **Jun I, Cheng MH, Sim E, Jung J, Suh BL, Kim Y, Son H, Park K, Kim CH, Yoon JH, Whitcomb DC, Bahar I, and Lee MG.** Pore dilatation increases the bicarbonate permeability of CFTR, ANO1 and glycine receptor anion channels. *J Physiol* 594: 2929-2955, 2016. [PMID: 26663196](#).

67. **Jung J, and Lee MG.** Role of calcium signaling in epithelial bicarbonate secretion. *Cell Calcium* 55: 376-384, 2014. [PMID: 24598807](#).
68. **Jung J, Nam JH, Park HW, Oh U, Yoon JH, and Lee MG.** Dynamic modulation of ANO1/TMEM16A HCO<sub>3</sub><sup>(-)</sup> permeability by Ca<sup>2+</sup>/calmodulin. *Proc Natl Acad Sci U S A* 110: 360-365, 2013. [PMID: 23248295](#).
69. **Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, and Tsui LC.** Identification of the cystic fibrosis gene: genetic analysis. *Science* 245: 1073-1080, 1989. [PMID: 2570460](#).
70. **Kim Y, Jun I, Shin DH, Yoon JG, Piao H, Jung J, Park HW, Cheng MH, Bahar I, Whitcomb DC, and Lee MG.** Regulation of CFTR Bicarbonate Channel Activity by WNK1: Implications for Pancreatitis and CFTR-Related Disorders. *Cell Mol Gastroenterol Hepatol* 9: 79-103, 2020. [PMID: 31561038](#).
71. **Kiselyov K, Wang X, Shin DM, Zang W, and Muallem S.** Calcium signaling complexes in microdomains of polarized secretory cells. *Cell Calcium* 40: 451-459, 2006. [PMID: 17034849](#).
72. **Knauf F, Yang CL, Thomson RB, Mentone SA, Giebisch G, and Aronson PS.** Identification of a chloride-formate exchanger expressed on the brush border membrane of renal proximal tubule cells. *Proc Natl Acad Sci U S A* 98: 9425-9430, 2001. [PMID: 11459928](#).
73. **Ko SB, Mizuno N, Yatabe Y, Yoshikawa T, Ishiguro H, Yamamoto A, Azuma S, Naruse S, Yamao K, Muallem S, and Goto H.** Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. *Gastroenterology* 138: 1988-1996, 2010. [PMID: 20080093](#).
74. **Ko SB, Naruse S, Kitagawa M, Ishiguro H, Furuya S, Mizuno N, Wang Y, Yoshikawa T, Suzuki A, Shimano S, and Hayakawa T.** Aquaporins in rat pancreatic interlobular ducts. *Am J Physiol Gastrointest Liver Physiol* 282: G324-331, 2002. [PMID: 11804854](#).
75. **Ko SB, Shcheynikov N, Choi JY, Luo X, Ishibashi K, Thomas PJ, Kim JY, Kim KH, Lee MG, Naruse S, and Muallem S.** A molecular mechanism for aberrant CFTR-dependent HCO<sub>3</sub><sup>(-)</sup> transport in cystic fibrosis. *EMBO J* 21: 5662-5672, 2002. [PMID: 12411484](#).
76. **Ko SB, Zeng W, Dorwart MR, Luo X, Kim KH, Millen L, Goto H, Naruse S, Soyombo A, Thomas PJ, and Muallem S.** Gating of CFTR by the STAS domain of SLC26 transporters. *Nat Cell Biol* 6: 343-350, 2004. [PMID: 15048129](#).
77. **Kohler H, Nustede R, Barthel M, and Schafmayer A.** Exocrine pancreatic function in dogs with denervated pancreas. *Pancreas* 2: 676-683, 1987. [PMID: 3325985](#).
78. **Konturek SJ, Zabielski R, Konturek JW, and Czarnecki J.** Neuroendocrinology of the pancreas; role of brain-gut axis in pancreatic secretion. *Eur J Pharmacol* 481: 1-14, 2003. [PMID: 14637169](#).
79. **Kowal JM, Yegutkin GG, and Novak I.** ATP release, generation and hydrolysis in exocrine pancreatic duct cells. *Purinergic Signal* 11: 533-550, 2015. [PMID: 26431833](#).
80. **Krishnan D, Liu L, Wiebe SA, Casey JR, Cordat E, and Alexander RT.** Carbonic anhydrase II binds to and increases the activity of the epithelial sodium-proton exchanger, NHE3. *Am J Physiol Renal Physiol* 309: F383-392, 2015. [PMID: 26041446](#).
81. **Kunzelmann K, Schreiber R, and Hadorn HB.** Bicarbonate in cystic fibrosis. *J Cyst Fibros* 16: 653-662, 2017. [PMID: 28732801](#).
82. **Kusiak AA, Szopa MD, Jakubowska MA, and Ferdek PE.** Signaling in the Physiology and Pathophysiology of Pancreatic Stellate Cells - a Brief Review of Recent Advances. *Front Physiol* 11: 78, 2020. [PMID: 32116785](#).
83. **LaRusch J, Jung J, General IJ, Lewis MD, Park HW, Brand RE, Gelrud A, Anderson MA, Banks PA, Conwell D, Lawrence C, Romagnuolo J, Baillie J, Alkaade S, Cote G, Gardner TB, Amann ST, Slivka A, Sandhu B, Aloe A, Kienholz ML, Yadav D, Barmada MM, Bahar I, Lee MG, Whitcomb DC, and North American Pancreatitis Study G.** Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. *PLoS Genet* 10: e1004376, 2014. [PMID: 25033378](#).
84. **Lee JH, Richter W, Namkung W, Kim KH, Kim E, Conti M, and Lee MG.** Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. *J Biol Chem* 282: 10414-10422, 2007. [PMID: 17244609](#).
85. **Lee MG, Ahn W, Choi JY, Luo X, Seo JT, Schultheis PJ, Shull GE, Kim KH, and Muallem S.** Na<sup>(+)</sup>-dependent transporters mediate HCO<sub>3</sub><sup>(-)</sup> salvage across the luminal membrane of the main pancreatic duct. *J Clin Invest* 105: 1651-1658, 2000. [PMID: 10841524](#).
86. **Lee MG, and Muallem S.** Physiology of duct cell secretion. In: *Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery*, edited by Beger H BM, Kozarek R, Lerch M, Neoptolemos J, Warshaw A, Whitcomb D, Shiratori K. . Oxford, U.K: Blackwell Publishing, 2008, p. 78-90.
87. **Lee MG, Ohana E, Park HW, Yang D, and Muallem S.** Molecular mechanism of pancreatic and salivary gland fluid and HCO<sub>3</sub> secretion. *Physiol Rev* 92: 39-74, 2012. [PMID: 22298651](#).

88. **Lee MG, Xu X, Zeng W, Diaz J, Wojcikiewicz RJ, Kuo TH, Wuytack F, Racymaekers L, and Muallem S.** Polarized expression of Ca<sup>2+</sup> channels in pancreatic and salivary gland cells. Correlation with initiation and propagation of [Ca<sup>2+</sup>]<sub>i</sub> waves. *J Biol Chem* 272: 15765-15770, 1997. [PMID: 9188472](#).
89. **Li X, Liu Y, Alvarez BV, Casey JR, and Fliegel L.** A novel carbonic anhydrase II binding site regulates NHE1 activity. *Biochemistry* 45: 2414-2424, 2006. [PMID: 16475831](#).
90. **Lifson N, Kramlinger KG, Mayrand RR, and Lender EJ.** Blood flow to the rabbit pancreas with special reference to the islets of Langerhans. *Gastroenterology* 79: 466-473, 1980. [PMID: 7000613](#).
91. **Lin WY, and Muallem S.** No Zoom Required: Meeting at the beta-Intercalated Cells. *J Am Soc Nephrol* 31: 1655-1657, 2020. [PMID: 32716314](#).
92. **Linsdell P, Tabcharani JA, Rommens JM, Hou YX, Chang XB, Tsui LC, Riordan JR, and Hanrahan JW.** Permeability of wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride channels to polyatomic anions. *J Gen Physiol* 110: 355-364, 1997. [PMID: 9379168](#).
93. **Liu F, Zhang Z, Csanady L, Gadsby DC, and Chen J.** Molecular Structure of the Human CFTR Ion Channel. *Cell* 169: 85-95 e88, 2017. [PMID: 28340353](#).
94. **Lohi H, Kujala M, Kerkela E, Saarialho-Kere U, Kestila M, and Kere J.** Mapping of five new putative anion transporter genes in human and characterization of SLC26A6, a candidate gene for pancreatic anion exchanger. *Genomics* 70: 102-112, 2000. [PMID: 11087667](#).
95. **Loiselle FB, Morgan PE, Alvarez BV, and Casey JR.** Regulation of the human NBC3 Na<sup>+</sup>/HCO<sub>3</sub><sup>-</sup> cotransporter by carbonic anhydrase II and PKA. *Am J Physiol Cell Physiol* 286: C1423-1433, 2004. [PMID: 14736710](#).
96. **Luo X, Zheng W, Yan M, Lee MG, and Muallem S.** Multiple functional P2X and P2Y receptors in the luminal and basolateral membranes of pancreatic duct cells. *Am J Physiol* 277: C205-215, 1999. [PMID: 10444396](#).
97. **Luscher BP, Vachel L, Ohana E, and Muallem S.** Cl<sup>-</sup> as a bona fide signaling ion. *Am J Physiol Cell Physiol* 318: C125-C136, 2020. [PMID: 31693396](#).
98. **Ma T, Song Y, Gillespie A, Carlson EJ, Epstein CJ, and Verkman AS.** Defective secretion of saliva in transgenic mice lacking aquaporin-5 water channels. *J Biol Chem* 274: 20071-20074, 1999. [PMID: 10400615](#).
99. **Madden ME, and Sarras MP, Jr.** Distribution of Na<sup>+</sup>,K<sup>+</sup>-ATPase in rat exocrine pancreas as monitored by K<sup>+</sup>-NPPase cytochemistry and [3H]-ouabain binding: a plasma membrane protein found primarily to be ductal cell associated. *J Histochem Cytochem* 35: 1365-1374, 1987. [PMID: 2824600](#).
100. **Marteau C, Blanc G, Devaux MA, Portugal H, and Gerolami A.** Influence of pancreatic ducts on saturation of juice with calcium carbonate in dogs. *Dig Dis Sci* 38: 2090-2097, 1993. [PMID: 8223086](#).
101. **Martinez JR.** Ion transport and water movement. *J Dent Res* 66 Spec No: 638-647, 1987. [PMID: 3305642](#).
102. **McKenna R, and Frost SC.** Overview of the carbonic anhydrase family. *Subcell Biochem* 75: 3-5, 2014. [PMID: 24146371](#).
103. **Melvin JE, Yule D, Shuttleworth T, and Begenisich T.** Regulation of fluid and electrolyte secretion in salivary gland acinar cells. *Annu Rev Physiol* 67: 445-469, 2005. [PMID: 15709965](#).
104. **Messenger SW, Falkowski MA, and Groblewski GE.** Ca<sup>2+</sup>(+)-regulated secretory granule exocytosis in pancreatic and parotid acinar cells. *Cell Calcium* 55: 369-375, 2014. [PMID: 24742357](#).
105. **Min X, Lee BH, Cobb MH, and Goldsmith EJ.** Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. *Structure* 12: 1303-1311, 2004. [PMID: 15242606](#).
106. **Muhammad E, Leventhal N, Parvari G, Hanukoglu A, Hanukoglu I, Chalifa-Caspi V, Feinstein Y, Weinbrand J, Jacoby H, Manor E, Nagar T, Beck JC, Sheffield VC, Hershkovitz E, and Parvari R.** Autosomal recessive hyponatremia due to isolated salt wasting in sweat associated with a mutation in the active site of Carbonic Anhydrase 12. *Hum Genet* 129: 397-405, 2011. [PMID: 21184099](#).
107. **Namkung W, Han W, Luo X, Muallem S, Cho KH, Kim KH, and Lee MG.** Protease-activated receptor 2 exerts local protection and mediates some systemic complications in acute pancreatitis. *Gastroenterology* 126: 1844-1859, 2004. [PMID: 15188179](#).
108. **Namkung W, Lee JA, Ahn W, Han W, Kwon SW, Ahn DS, Kim KH, and Lee MG.** Ca<sup>2+</sup> activates cystic fibrosis transmembrane conductance regulator- and Cl<sup>-</sup>-dependent HCO<sub>3</sub><sup>-</sup> transport in pancreatic duct cells. *J Biol Chem* 278: 200-207, 2003. [PMID: 12409301](#).
109. **Namkung W, Yoon JS, Kim KH, and Lee MG.** PAR2 exerts local protection against acute pancreatitis via modulation of MAP kinase and MAP kinase phosphatase signaling. *Am J Physiol Gastrointest Liver Physiol* 295: G886-894, 2008. [PMID: 18755806](#).
110. **Nguyen TD, Meichle S, Kim US, Wong T, and Moody MW.** P2Y<sub>11</sub>, a purinergic receptor acting via cAMP, mediates secretion by pancreatic duct epithelial cells. *Am J Physiol Gastrointest Liver Physiol* 280: G795-804, 2001. [PMID: 11292586](#).

111. **Nguyen TD, Moody MW, Steinhoff M, Okolo C, Koh DS, and Bunnett NW.** Trypsin activates pancreatic duct epithelial cell ion channels through proteinase-activated receptor-2. *J Clin Invest* 103: 261-269, 1999. [PMID: 9916138](#).
112. **North RA.** Molecular physiology of P2X receptors. *Physiol Rev* 82: 1013-1067, 2002. [PMID: 12270951](#).
113. **Novak I.** ATP as a signaling molecule: the exocrine focus. *News Physiol Sci* 18: 12-17, 2003. [PMID: 12531926](#).
114. **Novak I.** Purinergic receptors in the endocrine and exocrine pancreas. *Purinergic Signal* 4: 237-253, 2008. [PMID: 18368520](#).
115. **Novak I, and Greger R.** Electrophysiological study of transport systems in isolated perfused pancreatic ducts: properties of the basolateral membrane. *Pflügers Arch* 411: 58-68, 1988. [PMID: 3353213](#).
116. **Ohana E, Yang D, Shcheynikov N, and Muallem S.** Diverse transport modes by the solute carrier 26 family of anion transporters. *J Physiol* 587: 2179-2185, 2009. [PMID: 19015189](#).
117. **Ousingsawat J, Martins JR, Schreiber R, Rock JR, Harfe BD, and Kunzelmann K.** Loss of TMEM16A causes a defect in epithelial Ca<sup>2+</sup>-dependent chloride transport. *J Biol Chem* 284: 28698-28703, 2009. [PMID: 19679661](#).
118. **Pallagi P, Hegyi P, and Rakonczay Z, Jr.** The Physiology and Pathophysiology of Pancreatic Ductal Secretion: The Background for Clinicians. *Pancreas* 44: 1211-1233, 2015. [PMID: 26465950](#).
119. **Park HW, Nam JH, Kim JY, Namkung W, Yoon JS, Lee JS, Kim KS, Venglovecz V, Gray MA, Kim KH, and Lee MG.** Dynamic regulation of CFTR bicarbonate permeability by [Cl<sup>-</sup>]<sub>i</sub> and its role in pancreatic bicarbonate secretion. *Gastroenterology* 139: 620-631, 2010. [PMID: 20398666](#).
120. **Park M, Ko SB, Choi JY, Muallem G, Thomas PJ, Pushkin A, Lee MS, Kim JY, Lee MG, Muallem S, and Kurtz I.** The cystic fibrosis transmembrane conductance regulator interacts with and regulates the activity of the HCO<sub>3</sub><sup>-</sup> salvage transporter human Na<sup>+</sup>-HCO<sub>3</sub><sup>-</sup> cotransport isoform 3. *J Biol Chem* 277: 50503-50509, 2002. [PMID: 12403779](#).
121. **Park S, Hong JH, Ohana E, and Muallem S.** The WNK/SPAK and IRBIT/PP1 pathways in epithelial fluid and electrolyte transport. *Physiology (Bethesda)* 27: 291-299, 2012. [PMID: 23026752](#).
122. **Park S, Shcheynikov N, Hong JH, Zheng C, Suh SH, Kawaai K, Ando H, Mizutani A, Abe T, Kiyonari H, Seki G, Yule D, Mikoshiba K, and Muallem S.** Irbit mediates synergy between ca(2+) and cAMP signaling pathways during epithelial transport in mice. *Gastroenterology* 145: 232-241, 2013. [PMID: 23542070](#).
123. **Petersen OH.** Stimulus-excitation coupling in plasma membranes of pancreatic acinar cells. *Biochim Biophys Acta* 694: 163-184, 1982. [PMID: 6128029](#).
124. **Petersen OH, and Tepikin AV.** Polarized calcium signaling in exocrine gland cells. *Annu Rev Physiol* 70: 273-299, 2008. [PMID: 17850212](#).
125. **Piala AT, Moon TM, Akella R, He H, Cobb MH, and Goldsmith EJ.** Chloride sensing by WNK1 involves inhibition of autophosphorylation. *Sci Signal* 7: ra41, 2014. [PMID: 24803536](#).
126. **Poulsen JH, Fischer H, Illek B, and Machen TE.** Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. *Proc Natl Acad Sci U S A* 91: 5340-5344, 1994. [PMID: 7515498](#).
127. **Preshaw RM, Cooke AR, and Grossman MI.** Quantitative aspects of response of canine pancreas to duodenal acidification. *Am J Physiol* 210: 629-634, 1966. [PMID: 5933217](#).
128. **Pushkin A, Abuladze N, Lee I, Newman D, Hwang J, and Kurtz I.** Cloning, tissue distribution, genomic organization, and functional characterization of NBC3, a new member of the sodium bicarbonate cotransporter family. *J Biol Chem* 274: 16569-16575, 1999. [PMID: 10347222](#).
129. **Quinton PM.** Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. *Lancet* 372: 415-417, 2008. [PMID: 18675692](#).
130. **Quinton PM.** The neglected ion: HCO<sub>3</sub><sup>-</sup>. *Nat Med* 7: 292-293, 2001. [PMID: 11231624](#).
131. **Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, and et al.** Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 245: 1066-1073, 1989. [PMID: 2475911](#).
132. **Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, and et al.** Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science* 245: 1059-1065, 1989. [PMID: 2772657](#).
133. **Roos A, and Boron WF.** Intracellular pH. *Physiol Rev* 61: 296-434, 1981. [PMID: 7012859](#).
134. **Roussa E.** Channels and transporters in salivary glands. *Cell Tissue Res* 343: 263-287, 2011. [PMID: 21120532](#).
135. **Schaffalitzky de Muckadell OB, Fahrenkrug J, Watt-Boolsen S, and Worning H.** Pancreatic response and plasma secretin concentration during infusion of low dose secretin in man. *Scand J Gastroenterol* 13:

- 305-311, 1978. [PMID: 755275](#).
136. **Schroeder BC, Cheng T, Jan YN, and Jan LY.** Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. *Cell* 134: 1019-1029, 2008. [PMID: 18805094](#).
  137. **Shcheynikov N, Kim KH, Kim KM, Dorwart MR, Ko SB, Goto H, Naruse S, Thomas PJ, and Muallem S.** Dynamic control of cystic fibrosis transmembrane conductance regulator Cl(-)/HCO<sub>3</sub>(-) selectivity by external Cl(-). *J Biol Chem* 279: 21857-21865, 2004. [PMID: 15010471](#).
  138. **Shcheynikov N, Son A, Hong JH, Yamazaki O, Ohana E, Kurtz I, Shin DM, and Muallem S.** Intracellular Cl- as a signaling ion that potently regulates Na<sup>+</sup>/HCO<sub>3</sub><sup>-</sup> transporters. *Proc Natl Acad Sci U S A* 112: E329-337, 2015. [PMID: 25561556](#).
  139. **Shcheynikov N, Wang Y, Park M, Ko SB, Dorwart M, Naruse S, Thomas PJ, and Muallem S.** Coupling modes and stoichiometry of Cl-/HCO<sub>3</sub><sup>-</sup> exchange by slc26a3 and slc26a6. *J Gen Physiol* 127: 511-524, 2006. [PMID: 16606687](#).
  140. **Shcheynikov N, Yang D, Wang Y, Zeng W, Karniski LP, So I, Wall SM, and Muallem S.** The Slc26a4 transporter functions as an electroneutral Cl-/I-/HCO<sub>3</sub><sup>-</sup> exchanger: role of Slc26a4 and Slc26a6 in I- and HCO<sub>3</sub><sup>-</sup> secretion and in regulation of CFTR in the parotid duct. *J Physiol* 586: 3813-3824, 2008. [PMID: 18565999](#).
  141. **Shekarabi M, Zhang J, Khanna AR, Ellison DH, Delpire E, and Kahle KT.** WNK Kinase Signaling in Ion Homeostasis and Human Disease. *Cell Metab* 25: 285-299, 2017. [PMID: 28178566](#).
  142. **Shin DH, Kim M, Kim Y, Jun I, Jung J, Nam JH, Cheng MH, and Lee MG.** Bicarbonate permeation through anion channels: its role in health and disease. *Pflugers Arch* 472: 1003-1018, 2020. [PMID: 32621085](#).
  143. **Shirakabe K, Priori G, Yamada H, Ando H, Horita S, Fujita T, Fujimoto I, Mizutani A, Seki G, and Mikoshiba K.** IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein, specifically binds to and activates pancreas-type Na<sup>+</sup>/HCO<sub>3</sub><sup>-</sup> cotransporter 1 (pNBC1). *Proc Natl Acad Sci U S A* 103: 9542-9547, 2006. [PMID: 16769890](#).
  144. **Short DB, Trotter KW, Reczek D, Kreda SM, Bretscher A, Boucher RC, Stutts MJ, and Milgram SL.** An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. *J Biol Chem* 273: 19797-19801, 1998. [PMID: 9677412](#).
  145. **Smith ZD, Caplan MJ, Forbush B, 3rd, and Jamieson JD.** Monoclonal antibody localization of Na<sup>+</sup>-K<sup>+</sup>-ATPase in the exocrine pancreas and parotid of the dog. *Am J Physiol* 253: G99-109, 1987. [PMID: 2441610](#).
  146. **Sohma Y, Gray MA, Imai Y, and Argent BE.** HCO<sub>3</sub><sup>-</sup> transport in a mathematical model of the pancreatic ductal epithelium. *J Membr Biol* 176: 77-100, 2000. [PMID: 10882430](#).
  147. **Sohma Y, Gray MA, Imai Y, and Argent BE.** A mathematical model of the pancreatic ductal epithelium. *J Membr Biol* 154: 53-67, 1996. [PMID: 8881027](#).
  148. **Steward MC, Ishiguro H, and Case RM.** Mechanisms of bicarbonate secretion in the pancreatic duct. *Annu Rev Physiol* 67: 377-409, 2005. [PMID: 15709963](#).
  149. **Stewart AK, Yamamoto A, Nakakuki M, Kondo T, Alper SL, and Ishiguro H.** Functional coupling of apical Cl-/HCO<sub>3</sub><sup>-</sup> exchange with CFTR in stimulated HCO<sub>3</sub><sup>-</sup> secretion by guinea pig interlobular pancreatic duct. *Am J Physiol Gastrointest Liver Physiol* 296: G1307-1317, 2009. [PMID: 19342507](#).
  150. **Suzuki J, Umeda M, Sims PJ, and Nagata S.** Calcium-dependent phospholipid scrambling by TMEM16F. *Nature* 468: 834-838, 2010. [PMID: 21107324](#).
  151. **Terker AS, Zhang C, Erspamer KJ, Gamba G, Yang CL, and Ellison DH.** Unique chloride-sensing properties of WNK4 permit the distal nephron to modulate potassium homeostasis. *Kidney Int* 89: 127-134, 2016. [PMID: 26422504](#).
  152. **Ulrich CD, 2nd, Holtmann M, and Miller LJ.** Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors. *Gastroenterology* 114: 382-397, 1998. [PMID: 9453500](#).
  153. **Vachel L, Shcheynikov N, Yamazaki O, Fremder M, Ohana E, Son A, Shin DM, Yamazaki-Nakazawa A, Yang CR, Knepper MA, and Muallem S.** Modulation of Cl(-) signaling and ion transport by recruitment of kinases and phosphatases mediated by the regulatory protein IRBIT. *Sci Signal* 11: 2018. [PMID: 30377224](#).
  154. **Veel T, Villanger O, Holthe MR, Cragoe EJ, Jr., and Raeder MG.** Na(+)-H+ exchange is not important for pancreatic HCO<sub>3</sub><sup>-</sup> secretion in the pig. *Acta Physiol Scand* 144: 239-246, 1992. [PMID: 1316712](#).
  155. **Venglovecz V, Hegyi P, Rakonczay Z, Jr., Tiszlavicz L, Nardi A, Grunnet M, and Gray MA.** Pathophysiological relevance of apical large-conductance Ca(2<sup>+</sup>)-activated potassium channels in pancreatic duct epithelial cells. *Gut* 60: 361-369, 2011. [PMID: 20940280](#).
  156. **Venglovecz V, Pallagi P, Kemeny LV, Balazs A, Balla Z, Becskehazi E, Gal E, Toth E, Zvara A, Puskas LG, Borka K, Sandler M, Lerch MM, Mayerle J, Kuhn JP, Rakonczay Z, Jr., and Hegyi P.** The

- Importance of Aquaporin 1 in Pancreatitis and Its Relation to the CFTR Cl(-) Channel. *Front Physiol* 9: 854, 2018. [PMID: 30050452](#).
157. **Venglovecz V, Rakonczay Z, Jr., Ozsvari B, Takacs T, Lonovics J, Varro A, Gray MA, Argent BE, and Hegyi P.** Effects of bile acids on pancreatic ductal bicarbonate secretion in guinea pig. *Gut* 57: 1102-1112, 2008. [PMID: 18303091](#).
  158. **Vilas G, Krishnan D, Loganathan SK, Malhotra D, Liu L, Beggs MR, Gena P, Calamita G, Jung M, Zimmermann R, Tamma G, Casey JR, and Alexander RT.** Increased water flux induced by an aquaporin-1/carbonic anhydrase II interaction. *Mol Biol Cell* 26: 1106-1118, 2015. [PMID: 25609088](#).
  159. **Wang Y, Soyombo AA, Shcheynikov N, Zeng W, Dorwart M, Marino CR, Thomas PJ, and Muallem S.** Slc26a6 regulates CFTR activity in vivo to determine pancreatic duct HCO<sub>3</sub><sup>-</sup> secretion: relevance to cystic fibrosis. *EMBO J* 25: 5049-5057, 2006. [PMID: 17053783](#).
  160. **Willoughby D, and Cooper DM.** Organization and Ca<sup>2+</sup> regulation of adenylyl cyclases in cAMP microdomains. *Physiol Rev* 87: 965-1010, 2007. [PMID: 17615394](#).
  161. **Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, and Lifton RP.** Human hypertension caused by mutations in WNK kinases. *Science* 293: 1107-1112, 2001. [PMID: 11498583](#).
  162. **Wizemann V, and Schulz I.** Influence of amphotericin, amiloride, ionophores, and 2,4-dinitrophenol on the secretion of the isolated cat's pancreas. *Pflugers Arch* 339: 317-338, 1973. [PMID: 4735613](#).
  163. **Yang D, Li Q, So I, Huang CL, Ando H, Mizutani A, Seki G, Mikoshiba K, Thomas PJ, and Muallem S.** IRBIT governs epithelial secretion in mice by antagonizing the WNK/SPAK kinase pathway. *J Clin Invest* 121: 956-965, 2011. [PMID: 21317537](#).
  164. **Yang D, Shcheynikov N, and Muallem S.** IRBIT: it is everywhere. *Neurochem Res* 36: 1166-1174, 2011. [PMID: 21152975](#).
  165. **Yang D, Shcheynikov N, Zeng W, Ohana E, So I, Ando H, Mizutani A, Mikoshiba K, and Muallem S.** IRBIT coordinates epithelial fluid and HCO<sub>3</sub><sup>-</sup> secretion by stimulating the transporters pNBC1 and CFTR in the murine pancreatic duct. *J Clin Invest* 119: 193-202, 2009. [PMID: 19033647](#).
  166. **Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, Park SP, Lee J, Lee B, Kim BM, Raouf R, Shin YK, and Oh U.** TMEM16A confers receptor-activated calcium-dependent chloride conductance. *Nature* 455: 1210-1215, 2008. [PMID: 18724360](#).
  167. **You CH, Rominger JM, and Chey WY.** Potentiation effect of cholecystokinin-octapeptide on pancreatic bicarbonate secretion stimulated by a physiologic dose of secretin in humans. *Gastroenterology* 85: 40-45, 1983. [PMID: 6303892](#).
  168. **Zeng M, Szymczak M, Ahuja M, Zheng C, Yin H, Swaim W, Chiorini JA, Bridges RJ, and Muallem S.** Restoration of CFTR Activity in Ducts Rescues Acinar Cell Function and Reduces Inflammation in Pancreatic and Salivary Glands of Mice. *Gastroenterology* 153: 1148-1159, 2017. [PMID: 28634110](#).
  169. **Zeng W, Lee MG, and Muallem S.** Membrane-specific regulation of Cl<sup>-</sup> channels by purinergic receptors in rat submandibular gland acinar and duct cells. *J Biol Chem* 272: 32956-32965, 1997. [PMID: 9407075](#).
  170. **Zeng W, Lee MG, Yan M, Diaz J, Benjamin I, Marino CR, Kopito R, Freedman S, Cotton C, Muallem S, and Thomas P.** Immuno and functional characterization of CFTR in submandibular and pancreatic acinar and duct cells. *Am J Physiol* 273: C442-455, 1997. [PMID: 9277342](#).
  171. **Zhao H, and Muallem S.** Na<sup>+</sup>, K<sup>+</sup>, and Cl<sup>-</sup> transport in resting pancreatic acinar cells. *J Gen Physiol* 106: 1225-1242, 1995. [PMID: 8786358](#).
  172. **Zhao H, Star RA, and Muallem S.** Membrane localization of H<sup>+</sup> and HCO<sub>3</sub><sup>-</sup> transporters in the rat pancreatic duct. *J Gen Physiol* 104: 57-85, 1994. [PMID: 7964596](#).